Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Head and Neck Cancer

  Free Subscription


Articles published in Thyroid

Retrieve available abstracts of 379 articles:
HTML format



Single Articles


    March 2024
  1. STILLMAN M, Kuo EJ, Liou R, Almuqate A, et al
    Molecular Testing for Bethesda III Thyroid nodules: Trends in Implementation, Cytopathology Call Rates, Surgery Rates, and Malignancy Yield at a Single Institution.
    Thyroid. 2024 Mar 12. doi: 10.1089/thy.2023.0664.
    PubMed     Abstract available


    February 2024
  2. JIANG YJ, Xia Y, Hu Y, Han Z, et al
    Identification of P21 (CDKN1A) Activated Kinase 4 as a susceptibility gene for Familial Non-medullary Thyroid Carcinoma.
    Thyroid. 2024 Feb 27. doi: 10.1089/thy.2023.0564.
    PubMed     Abstract available


  3. SFREDDO HJ, Koh ES, Zhao K, Swartzwelder CE, et al
    RAS-Mutated Cytologically Indeterminate Thyroid Nodules: Prevalence of Malignancy and Behavior Under Active Surveillance.
    Thyroid. 2024 Feb 26. doi: 10.1089/thy.2023.0544.
    PubMed     Abstract available


  4. FERNANDEZ-VELASCO P, Perez Lopez P, Torres B, Delgado E, et al
    Clinical evaluation of an Artificial Intelligence-based decision support system for the diagnosis and ACR TI-RADS classification of thyroid nodules.
    Thyroid. 2024 Feb 18. doi: 10.1089/thy.2023.0603.
    PubMed     Abstract available


  5. PASCHKE R
    Why did the rapid increase of reflex molecular testing of indeterminate FNA cytologies in the USA not impact thyroidectomy rates? What is the lesson to be learned?
    Thyroid. 2024 Feb 12. doi: 10.1089/thy.2024.0042.
    PubMed     Abstract available


  6. ESPINOSA DE YCAZA AE, Brito JP, McCoy R, Shao H, et al
    GLP-1 receptor agonists and thyroid cancer: a narrative review.
    Thyroid. 2024 Feb 12. doi: 10.1089/thy.2023.0530.
    PubMed     Abstract available


  7. TAHARA M, Kiyota N, Imai H, Takahashi S, et al
    A phase II study of encorafenib in combination with binimetinib in patients with metastatic BRAF-mutated thyroid cancer in Japan.
    Thyroid. 2024 Feb 12. doi: 10.1089/thy.2023.0547.
    PubMed     Abstract available


    January 2024
  8. BROCK P, Liyanarachchi S, Nieminen TT, Chan C, et al
    CHEK2 founder variants and thyroid cancer risk.
    Thyroid. 2024 Jan 27. doi: 10.1089/thy.2023.0529.
    PubMed     Abstract available


  9. HUANG Y, Chan SJ, Wright JD, Kuo JH, et al
    Does the Adoption of Molecular Testing Cause Decreased Thyroidectomy Rates in a National Cohort? A Quasi-Experimental Study of High- Vs. Low-Adoption States.
    Thyroid. 2024 Jan 22. doi: 10.1089/thy.2023.0651.
    PubMed     Abstract available


  10. YANG F, Yang M, Liu Y, Zhou C, et al
    PDLIM7 promotes tumor metastasis in papillary thyroid carcinoma via stabilizing FAK protein.
    Thyroid. 2024 Jan 20. doi: 10.1089/thy.2023.0497.
    PubMed     Abstract available


  11. HAMIDI S, Iyer P, Dadu R, Gule-Monroe M, et al
    Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF(V600E) Mutated Anaplastic Thyroid Carcinoma.
    Thyroid. 2024 Jan 16. doi: 10.1089/thy.2023.0573.
    PubMed     Abstract available


  12. MIYAUCHI A
    Response to Xiang J. and Zhang H. re: "Active Surveillance Outcomes of Patients with Low-Risk Papillary Thyroid Microcarcinoma According to Levothyroxine Treatment Status".
    Thyroid. 2024 Jan 16. doi: 10.1089/thy.2023.0697.
    PubMed     Abstract available


  13. XIANG J, Zhang H
    Letter to the Editor: Active Surveillance Outcomes of Patients with Low-Risk Papillary Thyroid Microcarcinoma According to Levothyroxine Treatment Status.
    Thyroid. 2024 Jan 16. doi: 10.1089/thy.2023.0605.
    PubMed     Abstract available



  14. Correction to: Factors Associated with Survival in Anaplastic Thyroid Carcinoma: A Multicenter Study from the ENDOCAN-TUTHYREF Network by Jannin et al. Thyroid 2023;33(10):1190-1200; doi: 10.1089/thy.2023.0164.
    Thyroid. 2024;34:140.
    PubMed    


    December 2023
  15. TRAN TV, Schonfeld SJ, Pasqual E, Haymart MR, et al
    All-cause and cause-specific mortality among low-risk differentiated thyroid cancer survivors in the United States.
    Thyroid. 2023 Dec 27. doi: 10.1089/thy.2023.0449.
    PubMed     Abstract available


  16. PARK SK, Ryoo JH, Kim MH, Jung JY, et al
    Association between eight autoimmune diseases and thyroid cancer: A Nationwide Cohort Study.
    Thyroid. 2023 Dec 27. doi: 10.1089/thy.2023.0353.
    PubMed     Abstract available


  17. BERNARDI S, Rosolen V, Barbone F, Borgato S, et al
    Clinical outcomes of thermal ablation retreatment of benign thyroid nodules: A multicenter study from the Italian minimally-invasive treatments of the thyroid group.
    Thyroid. 2023 Dec 27. doi: 10.1089/thy.2023.0501.
    PubMed     Abstract available


  18. SHIRAI YT, Hoshi N, Ward JM, Liu H, et al
    Establishment and characterization of amitrole-induced mouse thyroid adenomatous nodule-derived cell lines.
    Thyroid. 2023 Dec 27. doi: 10.1089/thy.2023.0341.
    PubMed     Abstract available


  19. POMA AM, Macerola E, Ghossein R MD, Tallini G, et al
    Prevalence of differentiated high-grade thyroid carcinoma among well-differentiated tumors: a systematic review and meta-analysis.
    Thyroid. 2023 Dec 19. doi: 10.1089/thy.2023.0350.
    PubMed     Abstract available


  20. TAYLOR SR, Chiu AS, Hoxha I, Saucke MC, et al
    Assessing Fear of Thyroid Cancer in the General U.S. Population: A Cross-Sectional Study.
    Thyroid. 2023 Dec 19. doi: 10.1089/thy.2023.0479.
    PubMed     Abstract available


  21. CHENG SY, Kimura T, Doolittle WKL, Kruhlak M, et al
    Inhibition of MEK signaling attenuates cancer stem cell activity in anaplastic thyroid cancer.
    Thyroid. 2023 Dec 19. doi: 10.1089/thy.2023.0521.
    PubMed     Abstract available


  22. FEI-ZHANG D, Verma R, Arimoto R, Lawrence AS, et al
    Social Vulnerability Association with Thyroid Cancer Disparities in the United States.
    Thyroid. 2023 Dec 9. doi: 10.1089/thy.2023.0370.
    PubMed     Abstract available


  23. HURST ZA, Liyanarachchi S, Brock P, He H, et al
    Presumed Pathogenic Germline and Somatic Variants in African American Thyroid Cancer.
    Thyroid. 2023 Dec 7. doi: 10.1089/thy.2023.0487.
    PubMed     Abstract available


  24. CAPDEVILA J, Krajewska J, Hernando J, Robinson B, et al
    Increased progression-free survival with cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer irrespective of prior VEGFR-targeted therapy and tumor histology: a subgroup analysis of the COSMIC-311 study.
    Thyroid. 2023 Dec 7. doi: 10.1089/thy.2023.0463.
    PubMed     Abstract available


  25. CENSI S, Galuppini F, Clausi C, Battheu F, et al
    Tumor grade and molecular characteristics associated with survival in sporadic medullary thyroid carcinoma.
    Thyroid. 2023 Dec 4. doi: 10.1089/thy.2023.0482.
    PubMed     Abstract available


  26. CAVALLO AC, Pitoia F, Roberti J, Brenzoni P, et al
    Optimizing Diagnostic Accuracy of Fine Needle Aspiration Biopsy Calcitonin Measurements in Detecting Medullary Thyroid Carcinoma.
    Thyroid. 2023 Dec 4. doi: 10.1089/thy.2023.0313.
    PubMed     Abstract available


    November 2023
  27. PARK SJ, Kim M, Jeong S, Park YJ, et al
    Association Between Antibiotic Exposure and Thyroid Cancer: A Nationwide Cohort Study in South Korea.
    Thyroid. 2023 Nov 27. doi: 10.1089/thy.2023.0235.
    PubMed     Abstract available


  28. DE KOSTER EJ, Morreau H, Bleumink GS, van Engen-van Grunsven I, et al
    Molecular diagnostics and [18F]FDG-PET/CT in indeterminate thyroid nodules: complementing techniques or waste of valuable resources?
    Thyroid. 2023 Nov 27. doi: 10.1089/thy.2023.0337.
    PubMed     Abstract available


  29. SUBBIAH V, Hu MI, Mansfield AS, Taylor MH, et al
    Pralsetinib in Patients with Advanced/metastatic RET-altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study.
    Thyroid. 2023 Nov 27. doi: 10.1089/thy.2023.0363.
    PubMed     Abstract available


  30. CAMPBELL DJ, Estephan LE, Sina E, Mastrolonardo EV, et al
    Evaluating ChatGPT responses on thyroid nodules for patient education.
    Thyroid. 2023 Nov 27. doi: 10.1089/thy.2023.0491.
    PubMed     Abstract available


  31. ASSAAD S, Dov D, Park C, Davis R, et al
    A preliminary study comparing the performance of thyroid molecular tests to a deep learning algorithm in predicting malignancy in indeterminate thyroid fine needle aspiration biopsies.
    Thyroid. 2023 Nov 27. doi: 10.1089/thy.2023.0054.
    PubMed    


  32. KENNEDY E, Zhang C, Qadadha Y, Cheng CF, et al
    Rates of Detecting Thyroid Nodules Recommended for Biopsy with Ultrasound: Are All Indications Equal?
    Thyroid. 2023 Nov 19. doi: 10.1089/thy.2023.0234.
    PubMed     Abstract available


  33. TARASOVA VD, Tsai J, Masannat J, Hernandez-Prera J, et al
    Characterization of the thyroid cancer genomic landscape by plasma-based circulating tumor DNA next-generation sequencing.
    Thyroid. 2023 Nov 14. doi: 10.1089/thy.2023.0204.
    PubMed     Abstract available


  34. LI X, Peng C, Liu Y, Hu Y, et al
    Modified ACR TI-RADS and Modified AI TI-RADS for Thyroid Nodules: A Multicenter Retrospective Study.
    Thyroid. 2023 Nov 11. doi: 10.1089/thy.2023.0429.
    PubMed     Abstract available


  35. LEE I, Grice JV, Ji X, Chen Q, et al
    A Pilot Nonrandomized Controlled Trial Examining the Use of Artificial Tears on the Radioactivity of Tears after Radioactive Iodine Treatment for Thyroid Cancer.
    Thyroid. 2023 Nov 2. doi: 10.1089/thy.2023.0338.
    PubMed     Abstract available


  36. TORO-TOBON D, Morris JC 3rd, Hilger CR, Peskey C, et al
    Clinical outcomes of radioactive iodine redifferentiation therapy in previously iodine refractory differentiated thyroid cancers.
    Thyroid. 2023 Nov 2. doi: 10.1089/thy.2023.0456.
    PubMed     Abstract available


  37. MOOG S, Lamartina L, Bani MA, Al Ghuzlan A, et al
    Alkylating Agent-Induced High Tumor Mutational Burden in Medullary Thyroid Cancer and Response to Immune Checkpoint Inhibitors: Two Case Reports.
    Thyroid. 2023;33:1368-1373.
    PubMed     Abstract available


    October 2023
  38. LI X, Li Y, Yan L, Xiao J, et al
    Sonographic Evolution and Pathologic Findings of Papillary Thyroid Cancer after Radiofrequency Ablation: a 5-Year Retrospective Cohort Study.
    Thyroid. 2023 Oct 26. doi: 10.1089/thy.2023.0415.
    PubMed     Abstract available


  39. BACH K, Ansari P, Ansari H, Mott NM, et al
    Health-related Quality of Life in Patients with Low-risk Differentiated Thyroid Cancer: A Systematic Review Examining the Extent of Thyroidectomy.
    Thyroid. 2023 Oct 20. doi: 10.1089/thy.2023.0328.
    PubMed     Abstract available


  40. XU B, Viswanathan K, Ahadi MS, Ahmadi S, et al
    Association of the Genomic Profile of Medullary Thyroid Carcinoma with Tumor Characteristics and Clinical Outcomes in an International Multicenter Study.
    Thyroid. 2023 Oct 16. doi: 10.1089/thy.2023.0279.
    PubMed     Abstract available


  41. JANNIN A, Giudici F, de la Fouchardiere C, Al Ghuzlan A, et al
    Factors Associated with Survival in Anaplastic Thyroid Carcinoma: A Multicenter Study from the ENDOCAN-TUTHYREF Network.
    Thyroid. 2023;33:1190-1200.
    PubMed     Abstract available


    September 2023
  42. PAPADOPOULOU A, Asvold BO, Burgess S, Kus A, et al
    Height, autoimmune thyroid disease and thyroid cancer: a Mendelian randomisation study.
    Thyroid. 2023 Sep 29. doi: 10.1089/thy.2023.0272.
    PubMed     Abstract available


  43. STEWARDSON P, Eszlinger M, Wu J, Khalil M, et al
    Prospective Validation of ThyroSPEC Molecular Testing of Indeterminate Thyroid Nodule Cytology Following Diagnostic Pathway Optimization.
    Thyroid. 2023 Sep 24. doi: 10.1089/thy.2023.0255.
    PubMed     Abstract available


  44. XIAO X, Chen M, Sang Y, Xue J, et al
    Methylation-mediated silencing of ATF3 promotes thyroid cancer progression by regulating prognostic genes in the MAPK and PI3K/AKT pathways.
    Thyroid. 2023 Sep 24. doi: 10.1089/thy.2023.0157.
    PubMed     Abstract available


  45. GUPTA M, Misariu AM, Saydy N, Nichols A, et al
    A Multicentre Retrospective Study of Anaplastic Thyroid Cancer in the Era of Targeted Therapy in a Public Health Care System: Canada's Experience.
    Thyroid. 2023 Sep 19. doi: 10.1089/thy.2023.0088.
    PubMed     Abstract available


  46. DE LEO S, D'Elia S, Grani G, Dondi F, et al
    A Prospective, Multicenter Study Examining the Relationship between Thyroid Cancer Treatment Outcomes and the Presence of Autoimmune Thyroiditis.
    Thyroid. 2023 Sep 19. doi: 10.1089/thy.2023.0052.
    PubMed     Abstract available


  47. BALAKIROUCHENANE D, Seban R, Groussin L, Puszkiel A, et al
    Pharmacokinetics/Pharmacodynamics of dabrafenib and trametinib for redifferentiation and treatment of radioactive-iodine-resistant mutated advanced differentiated thyroid cancer.
    Thyroid. 2023 Sep 19. doi: 10.1089/thy.2023.0228.
    PubMed     Abstract available


  48. BIONDI B MD, Pucci M, Pontieri G, Formisano P, et al
    PRELIMINARY RESULTS OF A DOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL EVALUATING THE CARDIO-METABOLIC EFFECTS OF LEVOTHYROXINE AND LIOTHYRONINE COMPARED TO LEVOTHYROXINE WITH PLACEBO IN ATHYREOTIC LOW RISK THYROID CANCER PATIENTS.
    Thyroid. 2023 Sep 19. doi: 10.1089/thy.2023.0135.
    PubMed     Abstract available


  49. GUNDA V, Ghosh C, Hu J, Zhang L, et al
    Combination BRAFV600E inhibition with the multitargeting tyrosine kinase inhibitor axitinib shows additive anticancer activity in BRAFV600E-mutant anaplastic thyroid cancer.
    Thyroid. 2023 Sep 7. doi: 10.1089/thy.2023.0201.
    PubMed     Abstract available


  50. FAGIN JA, Nikiforov YE
    Progress in Thyroid Cancer Genomics: A 40-Year Journey.
    Thyroid. 2023 Sep 4. doi: 10.1089/thy.2023.0045.
    PubMed     Abstract available


    August 2023
  51. SINCLAIR CF, Baek JH, Hands KE, Hodak SP, et al
    General principles for the safe performance, training and adoption of ablation techniques for benign thyroid nodules: An American Thyroid Association Statement.
    Thyroid. 2023 Aug 29. doi: 10.1089/thy.2023.0281.
    PubMed     Abstract available


  52. PAK SJ, Kwon D, Kim BC, Cho JW, et al
    Contralateral Low-to-Intermediate Suspicion Nodule is Not a Contraindication for Lobectomy in Patients with Papillary Thyroid Carcinoma.
    Thyroid. 2023 Aug 25. doi: 10.1089/thy.2023.0270.
    PubMed     Abstract available


  53. ROSS DS
    Response to Yan et al. re "Could Radioactive Iodine be a Preferred Therapy for Graves' Hyperthyroidism Patients with Large Goiters? A Viewpoint from China.
    Thyroid. 2023 Aug 25. doi: 10.1089/thy.2023.0423.
    PubMed     Abstract available


  54. TUTTLE RM MD
    Is there a role for levothyroxine therapy in euthyroid patients on active surveillance for papillary microcarcinomas?
    Thyroid. 2023 Aug 19. doi: 10.1089/thy.2023.0424.
    PubMed     Abstract available


  55. SALAS-LUCIA F, Liao XH, Jiang H, Dumitrescu AM, et al
    The Relationship between Fetal THRB Genotype and Maternal Thyroid Function.
    Thyroid. 2023 Aug 19. doi: 10.1089/thy.2023.0236.
    PubMed     Abstract available


  56. BANG JI, Park S, Kim K, Seo Y, et al
    The Diagnostic Value of F-18 FDG PET/CT in Differentiated Thyroid Cancer Patients with Elevated Thyroglobulin/Thyroglobulin Antibody Levels and Negative Iodine Scintigraphy: A Systematic Review and Meta-analysis.
    Thyroid. 2023 Aug 19. doi: 10.1089/thy.2023.0264.
    PubMed     Abstract available


  57. YAN S, Li X, Yan B
    Letter to the Editor: Could Radioactive Iodine Be a Preferred Therapy for Graves' Hyperthyroidism Patients with Large Goiters? A Viewpoint from China.
    Thyroid. 2023 Aug 18. doi: 10.1089/thy.2023.0332.
    PubMed    


  58. WADSLEY J, Ainsworth G, Coulson AB, Garcez K, et al
    Results of the SEL-I-METRY phase II trial on resensitisation of advanced iodine refractory differentiated thyroid cancer to radioiodine therapy.
    Thyroid. 2023 Aug 11. doi: 10.1089/thy.2022.0707.
    PubMed     Abstract available


  59. LEVINE RA
    History of Thyroid Ultrasound.
    Thyroid. 2023;33:894-902.
    PubMed     Abstract available


    July 2023
  60. SAHAKIAN N, Romanet P, Mirebeau-Prunier D, Paladino C, et al
    Letter to the Editor: The Somatic RET M918T Variant May Modify the Natural History of Germline RET L790F MEN2-Related Medullary Thyroid Carcinoma.
    Thyroid. 2023 Jul 19. doi: 10.1089/thy.2023.0110.
    PubMed    


  61. DE LEO S, Trevisan M, Re Sarto GV, Moneta C, et al
    TUMOR LYSIS SYNDROME DURING SELPERCATINIB TREATMENT IN A PATIENT WITH MEDULLARY THYROID CANCER.
    Thyroid. 2023 Jul 18. doi: 10.1089/thy.2023.0214.
    PubMed    


  62. SINGER S, Al-Ibraheem A, Pinto M, Iakovou I, et al
    International phase IV field study for the reliability and validity of the European Organisation for Research and Treatment of Cancer Thyroid Cancer Module EORTC QLQ-THY34.
    Thyroid. 2023 Jul 14. doi: 10.1089/thy.2023.0221.
    PubMed     Abstract available


  63. ALI SZ, Baloch ZW, Cochand-Priollet B, Schmitt FC, et al
    The 2023 Bethesda System for Reporting Thyroid Cytopathology.
    Thyroid. 2023 Jul 8. doi: 10.1089/thy.2023.0141.
    PubMed     Abstract available


    June 2023
  64. MARCZYK VR, Recamonde-Mendoza M, Maia AL, Goemann IM, et al
    Classification of Thyroid Tumors Based on DNA Methylation Patterns.
    Thyroid. 2023 Jun 30. doi: 10.1089/thy.2023.0074.
    PubMed     Abstract available


  65. LEBOULLEUX S, Benisvy D, Taieb D, Attard M, et al
    MERAIODE: A Phase II Redifferentiation Trial with Trametinib and 131I in Metastatic Radioactive Iodine Refractory RAS Mutated Differentiated thyroid Cancer.
    Thyroid. 2023 Jun 23. doi: 10.1089/thy.2023.0240.
    PubMed     Abstract available


  66. O'NEILL C, Carlson M, Rowe C, Fradgley E, et al
    Hearing the voices of Australian thyroid cancer survivors: qualitative thematic analysis of semi-structured interviews identifies unmet support needs.
    Thyroid. 2023 Jun 19. doi: 10.1089/thy.2023.0080.
    PubMed     Abstract available


  67. YAMAMOTO M, Miyauchi A, Ito Y, Fujishima M, et al
    Active Surveillance Outcomes of Patients with Low-risk Papillary Thyroid Microcarcinoma According to Levothyroxine Treatment Status.
    Thyroid. 2023 Jun 13. doi: 10.1089/thy.2023.0046.
    PubMed     Abstract available


  68. BAUDIN C, Bressand A, Buffet C, Menegaux F, et al
    Dysfunction of the salivary and lacrimal glands after radioiodine therapy for thyroid cancer: Results of the START study after 6-months of follow-up.
    Thyroid. 2023 Jun 10. doi: 10.1089/thy.2023.0090.
    PubMed     Abstract available


  69. TORO-TOBON D, Loor-Torres R, Duran M, Fan JW, et al
    Artificial Intelligence in Thyroidology: A Narrative Review of the Current Applications, Associated Challenges, and Future Directions.
    Thyroid. 2023 Jun 6. doi: 10.1089/thy.2023.0132.
    PubMed     Abstract available


  70. PAPINI E, Hegedus L
    Minimally Invasive Ablative Treatments for Benign Thyroid Nodules: Current Evidence and Future Directions.
    Thyroid. 2023 Jun 2. doi: 10.1089/thy.2023.0263.
    PubMed    


  71. DANIELS GH, Ross DS
    Radioactive Iodine: A Living History.
    Thyroid. 2023;33:666-673.
    PubMed     Abstract available


    May 2023
  72. BOGSRUD TV, Jacobsen M, Durski JM, Engelsen O, et al
    Repeat Redifferentiation of Radioiodine Refractory BRAFV600E Mutated Thyroid Cancer With Dabrafenib.
    Thyroid. 2023 May 22. doi: 10.1089/thy.2022.0651.
    PubMed     Abstract available


  73. IESATO A, Li S, Sadow PM, Abbasian M, et al
    The tyrosine kinase inhibitor lenvatinib inhibits anaplastic thyroid carcinoma growth by targeting pericytes in the tumor microenvironment.
    Thyroid. 2023 May 12. doi: 10.1089/thy.2022.0597.
    PubMed     Abstract available


  74. BALLAL S, Yadav MP, Roesch F, Raju S, et al
    Head-to-head comparison of [68Ga]Ga-DOTA.SA.FAPi and [68Ga]Ga-DOTANOC PET/CT imaging for the follow-up surveillance of patients with medullary thyroid cancer.
    Thyroid. 2023 May 12. doi: 10.1089/thy.2023.0008.
    PubMed     Abstract available


  75. MIYAUCHI A, Ito Y, Fujishima M, Miya A, et al
    Long-term outcomes of active surveillance and immediate surgery for adult patients with low-risk papillary thyroid microcarcinoma: 30-year experience.
    Thyroid. 2023 May 11. doi: 10.1089/thy.2023.0076.
    PubMed     Abstract available


  76. CHORTI A, Bontinis V, Tzikos G, Bontinis A, et al
    Minimally invasive treatments of benign thyroid nodules: a network meta-analysis of short-term outcomes.
    Thyroid. 2023 May 11. doi: 10.1089/thy.2022.0671.
    PubMed     Abstract available


  77. GHOSSEIN R, Ganly I, Tuttle RM, Xu B, et al
    Large (>4 cm) Intrathyroidal Encapsulated Well-Differentiated Follicular Cell-Derived Carcinoma Without Vascular Invasion May Have Negligible Risk of Recurrence Even When Treated with Lobectomy Alone.
    Thyroid. 2023;33:586-592.
    PubMed     Abstract available


    April 2023
  78. SHAN Z, Li Y, Li Y, Wang H, et al
    Changing iodine status and the incidence of thyroid disease in mainland China: A prospective 20-year follow-up study.
    Thyroid. 2023 Apr 21. doi: 10.1089/thy.2022.0505.
    PubMed     Abstract available


  79. LOPEZ B, Fligor SC, Randolph GW, James BC, et al
    Inequities in Thyroid Cancer Care: Populations Most at Risk for Delays in Diagnosis and Treatment.
    Thyroid. 2023 Apr 13. doi: 10.1089/thy.2022.0723.
    PubMed     Abstract available


  80. KHANAL T, Rajan N, Li W, Liyanarachchi S, et al
    The RCAN1.4 metastasis suppressor is hypermethylated at intron 1 in thyroid cancer.
    Thyroid. 2023 Apr 13. doi: 10.1089/thy.2022.0687.
    PubMed     Abstract available


  81. COLLINS R, Chaves N, Lee GJ, Broekhuis J, et al
    Urban and Rural Surgical Practice Patterns for Papillary Thyroid Carcinoma.
    Thyroid. 2023 Apr 4. doi: 10.1089/thy.2022.0711.
    PubMed     Abstract available


  82. LEBBINK CA, van Santen HM, Daneman A, Wasserman JD, et al
    Does ultrasound really contribute to detection of residual/recurrent disease after pediatric thyroidectomy? Preliminary data supporting a "thyroglobulin-first" approach.
    Thyroid. 2023 Apr 4. doi: 10.1089/thy.2022.0576.
    PubMed     Abstract available


  83. BRANDLER TC, Zhou F, Liu CZ, Serrano A, et al
    Molecular Profiles of Non-Invasive, Minimally Invasive and Invasive Follicular Patterned Thyroid Neoplasms with Papillary Nuclear Features.
    Thyroid. 2023 Apr 4. doi: 10.1089/thy.2023.0047.
    PubMed     Abstract available


    March 2023
  84. LIU JB, Baugh KA, Ramonell K, McCoy KL, et al
    Molecular Testing Predicts Incomplete Response to Initial Therapy in Differentiated Thyroid Carcinoma without Lateral Neck or Distant Metastasis at Presentation: Retrospective Cohort Study.
    Thyroid. 2023 Mar 27. doi: 10.1089/thy.2023.0060.
    PubMed     Abstract available


  85. ALSHARIF O, Panella T, Nodit L, Hu MI, et al
    ETV6-NTRK2 Fusion Identified in a Patient with Medullary Thyroid Carcinoma.
    Thyroid. 2023 Mar 24. doi: 10.1089/thy.2022.0630.
    PubMed     Abstract available


  86. BIKAS A, Wong K, Pappa T, Ahmadi S, et al
    Papillary Thyroid Carcinomas with Tall Cell Features: An Intermediate Entity between Classic and Tall Cell Subtypes.
    Thyroid. 2023 Mar 24. doi: 10.1089/thy.2022.0534.
    PubMed     Abstract available


  87. ALZUMAILI B, Krumeich LN, Collins R, Kravchenko T, et al
    A Comprehensive Study on the Diagnosis and Management of Non-Invasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP).
    Thyroid. 2023 Mar 24. doi: 10.1089/thy.2023.0035.
    PubMed     Abstract available


  88. GILD ML, Bullock M, Tsang V, Clifton-Bligh R, et al
    Challenges and strategies to combat resistance mechanisms in thyroid cancer therapeutics.
    Thyroid. 2023 Mar 16. doi: 10.1089/thy.2022.0704.
    PubMed     Abstract available


    February 2023
  89. SHAHA AR
    Anaplastic Thyroid Cancer: Shifting Paradigms-A Ray of Hope.
    Thyroid. 2023 Feb 28. doi: 10.1089/thy.2023.29150.
    PubMed    


  90. KWON D, Kulich M, Mack WJ, Martinez Monedero R, et al
    Malignancy Risk of Thyroid Nodules That Are Not Classifiable by the ATA Ultrasound Risk Stratification System: A Systematic Review and Meta-Analysis.
    Thyroid. 2023 Feb 28. doi: 10.1089/thy.2022.0672.
    PubMed     Abstract available


  91. CORRIVEAU-PARENTEAU E, Turkdogan S, Noik M, Forest VI, et al
    Clinical Experience of Cytologically Indeterminate Thyroid Nodules Designated as Negative on Molecular Testing Using Thyroseq V3: A Retrospective Cohort Study.
    Thyroid. 2023 Feb 24. doi: 10.1089/thy.2022.0555.
    PubMed     Abstract available


  92. CHOU R, Dana T, Mayson SE, Cibas ES, et al
    Ultrasound Follow-up of Benign Thyroid Nodules: A Scoping Review.
    Thyroid. 2023 Feb 18. doi: 10.1089/thy.2022.0692.
    PubMed     Abstract available


  93. OLEINIKOV K, Yaakov E, Mizrachi A, Hirsch D, et al
    A Comparison of Outcomes in Medullary Thyroid Carcinoma Patients with and without a Preoperative Diagnosis: A Multicenter Retrospective Cohort Study.
    Thyroid. 2023 Feb 15. doi: 10.1089/thy.2022.0424.
    PubMed     Abstract available


  94. CHEN C, Cao J, Wang Y, Han X, et al
    Health-related quality of life and thyroid cancer-specific symptoms in patients treated for differentiated thyroid cancer: a single center, cross-sectional survey from Mainland China.
    Thyroid. 2023 Feb 15. doi: 10.1089/thy.2022.0490.
    PubMed     Abstract available


  95. SUGISAWA C, Narumi S, Tanase-Nakao K, Ayako H, et al
    Adult Thyroid Outcomes of Congenital Hypothyroidism.
    Thyroid. 2023 Feb 15. doi: 10.1089/thy.2022.0481.
    PubMed     Abstract available


  96. VAN NOSTRAND D, Vetysman I, Kulkarni K, Heimlich SL, et al
    Redifferentiation of Differentiated Thyroid Cancer: Clinical Insights from a Narrative Review of Literature.
    Thyroid. 2023 Feb 15. doi: 10.1089/thy.2022.0632.
    PubMed     Abstract available


  97. WANG Z, Guan H
    Hear the Patient's Voice Regarding Implementation of Thyroid Cancer Active Surveillance in China.
    Thyroid. 2023 Feb 15. doi: 10.1089/thy.2023.0058.
    PubMed     Abstract available


  98. HIRSCH D, Yackobovitch-Gavan M, Lazar L
    Infertility and Pregnancy Rates in Female Thyroid Cancer Survivors: A Retrospective Cohort Study Using Healthcare Administrative Data from Israel.
    Thyroid. 2023 Feb 14. doi: 10.1089/thy.2022.0501.
    PubMed     Abstract available


  99. ZHAO X, Wang JR, Dadu R, Busaidy N, et al
    Surgery after BRAF-directed therapy is associated with improved survival in BRAF V600E mutant Anaplastic Thyroid Cancer.
    Thyroid. 2023 Feb 10. doi: 10.1089/thy.2022.0504.
    PubMed     Abstract available


  100. WADSLEY J
    Redifferentiation therapy for iodine refractory differentiated thyroid cancers- current status.
    Thyroid. 2023 Feb 6. doi: 10.1089/thy.2023.0057.
    PubMed     Abstract available


    January 2023
  101. ZHU P, Zhang Q, Wu Q, Shi G, et al
    Barriers and Facilitators to the Choice of Active Surveillance for Low-risk Papillary Thyroid Cancer in China: A Qualitative Study Examining Patient Perspectives.
    Thyroid. 2023 Jan 31. doi: 10.1089/thy.2022.0347.
    PubMed     Abstract available


  102. BARBI WALTER L, Scheffel RS, Zanella AB, Farenzena M, et al
    Active Surveillance of Differentiated Thyroid Cancer Metastatic Cervical Lymph Nodes: A Retrospective Single-Center Cohort Study.
    Thyroid. 2023 Jan 21. doi: 10.1089/thy.2022.0542.
    PubMed     Abstract available


  103. WIJEWARDENE A, Bastard K, Wang B, Gild M, et al
    A Case Report of Poor Response to Selpercatinib in the Presence of a 632_633 RET Deletion.
    Thyroid. 2023;33:119-125.
    PubMed     Abstract available


    December 2022
  104. NIKITSKI AV, Condello V, Divakaran SS, Nikiforov YE, et al
    Inhibition of ALK-Signaling Overcomes STRN-ALK-Induced Downregulation of the Sodium Iodine Symporter and Restores Radioiodine Uptake in Thyroid Cells.
    Thyroid. 2022 Dec 31. doi: 10.1089/thy.2022.0533.
    PubMed     Abstract available


  105. CHEN YH, Cabanillas M, Sperling J, Xu L, et al
    Prior thyroid and non-thyroid cancer history do not significantly alter overall survival in patients diagnosed with anaplastic thyroid carcinoma.
    Thyroid. 2022 Dec 13. doi: 10.1089/thy.2022.0350.
    PubMed     Abstract available


  106. CONTRERA KJ, Gule-Monroe M, Hu MI, Cabanillas M, et al
    Neoadjuvant Selective RET Inhibitor for Medullary Thyroid Cancer: A Case Series.
    Thyroid. 2022 Dec 11. doi: 10.1089/thy.2022.0506.
    PubMed     Abstract available


    November 2022
  107. TESSLER FN, Thomas J
    Artificial Intelligence for Evaluation of Thyroid Nodules: A Primer.
    Thyroid. 2022 Nov 24. doi: 10.1089/thy.2022.0560.
    PubMed     Abstract available


  108. WILHELM A, Conroy PC, Calthorpe L, Shui AM, et al
    Disease-Specific Survival Trends for Patients Presenting with Differentiated Thyroid Cancer and Distant Metastases in the United States, 1992-2018.
    Thyroid. 2022 Nov 18. doi: 10.1089/thy.2022.0353.
    PubMed     Abstract available


  109. THIESMEYER JW, Egan C, Greenberg JA, Beninato T, et al
    Prepubertal Children with Papillary Thyroid Carcinoma Present with More Invasive Disease than Adolescents and Young Adults.
    Thyroid. 2022 Nov 10. doi: 10.1089/thy.2022.0098.
    PubMed     Abstract available


  110. KITAHARA CM
    Obesity, physical activity, and thyroid cancer risk - disentangling true associations from detection bias.
    Thyroid. 2022 Nov 9. doi: 10.1089/thy.2022.0618.
    PubMed     Abstract available


  111. SHOBAB L, Wartofsky L
    Perspective: The Molecular Landscape of Radioactive Iodine Refractory Differentiated Thyroid Cancer and Poorly Differentiated Thyroid Cancer.
    Thyroid. 2022 Nov 7. doi: 10.1089/thy.2022.0428.
    PubMed     Abstract available


  112. DE LEO S, Trevisan M, Colombo C, Moneta C, et al
    HYPOCALCEMIA DURING LENVATINIB TREATMENT FOR ADVANCED THYROID CANCER: CLINICAL FEATURES AND MANAGEMENT IN A REAL-LIFE SETTING.
    Thyroid. 2022 Nov 3. doi: 10.1089/thy.2022.0439.
    PubMed     Abstract available


  113. DAVIS S, Ullmann TM, Roman S
    Disparities in Treatment for Differentiated Thyroid Cancer.
    Thyroid. 2022 Nov 3. doi: 10.1089/thy.2022.0432.
    PubMed     Abstract available


  114. DONG W, Okamoto T, Ji X, Xiang J, et al
    Conditional Survival Rate Estimates for Anaplastic Thyroid Cancer Beyond the First Year: An Analysis of SEER Data (2004 to 2019).
    Thyroid. 2022 Nov 3. doi: 10.1089/thy.2022.0339.
    PubMed     Abstract available


  115. LINKS MH, Lefrandt JD, Lisman T, van der Boom T, et al
    Fluctuations in thyroid hormone levels during initial treatment for differentiated thyroid carcinoma are associated with changes in hemostasis: a prospective cohort study.
    Thyroid. 2022 Nov 2. doi: 10.1089/thy.2022.0299.
    PubMed     Abstract available


  116. TANEJA C, Yip L, Morariu EM, Seethala R, et al
    Clinicopathologic Characteristics and Postsurgical Follow-Up of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features in the Postnomenclature Revision Era.
    Thyroid. 2022;32:1346-1352.
    PubMed     Abstract available


    October 2022
  117. WILDMAN-TOBRINER B, Hoang JK
    Incidental Thyroid Nodules on CT: A Radiologist's Perspective.
    Thyroid. 2022 Oct 19. doi: 10.1089/thy.2022.0553.
    PubMed     Abstract available


  118. GARCIA-LOZANO CA, Sanabria A
    Preliminary report of active surveillance as a conservative strategy for Bethesda IV thyroid nodules.
    Thyroid. 2022 Oct 17. doi: 10.1089/thy.2022.0296.
    PubMed     Abstract available


  119. WU J, Hu XY, Ghaznavi S, Kinnear S, et al
    The Prospective Implementation of the 2015 ATA Guidelines and Modified ATA Recurrence Risk Stratification System for Treatment of Differentiated Thyroid Cancer in a Canadian Tertiary Care Referral Setting.
    Thyroid. 2022 Oct 13. doi: 10.1089/thy.2022.0055.
    PubMed     Abstract available


  120. DUVAL MADS, Ferreira CV, Marmitt L, Dora JM, et al
    An undetectable postoperative calcitonin level is associated with long-term disease-free survival in medullary thyroid carcinoma: Results of a retrospective cohort study.
    Thyroid. 2022 Oct 12. doi: 10.1089/thy.2022.0295.
    PubMed     Abstract available


  121. SASAKI T, Miyauchi A, Fujishima M, Ito Y, et al
    Comparison of postoperative unfavorable events in patients with low-risk papillary thyroid carcinoma: Immediate surgery vs. conversion surgery following active surveillance.
    Thyroid. 2022 Oct 7. doi: 10.1089/thy.2022.0444.
    PubMed     Abstract available


  122. HO AS, Bastien AJ, Sacks W
    Thyroid Cancer Active Surveillance: The Devil You Know Or The Devil You Don't.
    Thyroid. 2022 Oct 7. doi: 10.1089/thy.2022.0541.
    PubMed     Abstract available


  123. LEE EK, Moon JH, Hwangbo Y, Ryu CH, et al
    Progression of Low-risk Papillary Thyroid Microcarcinoma During Active Surveillance: Interim analysis of a Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma (MAeSTro) in Korea.
    Thyroid. 2022 Oct 7. doi: 10.1089/thy.2021.0614.
    PubMed     Abstract available


  124. GOLDFARB M, Franco A
    SURVIVORSHIP, QUALITY OF LIFE, AND TRANSITION TO ADULT CARE FOR PEDIATRIC AND ADOLESCENT THYROID CANCER SURVIVORS.
    Thyroid. 2022 Oct 3. doi: 10.1089/thy.2022.0407.
    PubMed     Abstract available


    September 2022
  125. TUTTLE RM MD, Fagin JA, Minkowitz G, Wong RJ, et al
    Active surveillance of papillary thyroid cancer-frequency and time course of the 6 most common tumor volume kinetic patterns.
    Thyroid. 2022 Sep 30. doi: 10.1089/thy.2022.0325.
    PubMed     Abstract available


  126. GUILMETTE J, Dias-Santagata D, Lennerz JK, Selig MK, et al
    Primary Thyroid Neoplasm with Fetal Morphology Associated with DICER1 Mutations: Expanding the Diagnostic Profile of Thyroblastoma.
    Thyroid. 2022 Sep 30. doi: 10.1089/thy.2022.0060.
    PubMed     Abstract available


  127. SORENSEN SM, Urbute A, Frederiksen K, Kjaer SK, et al
    Pre-pregnancy Body Mass Index and risk of differentiated thyroid cancer: a prospective cohort study of more than 440,000 Danish women.
    Thyroid. 2022 Sep 29. doi: 10.1089/thy.2022.0259.
    PubMed     Abstract available


  128. HE Q, Cao H, Zhao Y, Chen P, et al
    DPP4 stabilizes integrin alpha4beta1 complex to promote thyroid cancer cell metastasis by activating TGF-beta signaling pathway.
    Thyroid. 2022 Sep 27. doi: 10.1089/thy.2022.0317.
    PubMed     Abstract available


  129. LEE H, Krishnan V, Wirth LJ, Nucera C, et al
    Case Report of CCDC149-ALK fusion: a novel genetic alteration and a clinically relevant target in metastatic papillary thyroid carcinoma.
    Thyroid. 2022 Sep 23. doi: 10.1089/thy.2022.0389.
    PubMed     Abstract available


  130. DRAKE T, Gravely A, Ensrud K, Billington CJ, et al
    Reporting of Incidental Thyroid Nodules on Chest CT and the Impact on Nodule Evaluation: A Retrospective Cohort Study.
    Thyroid. 2022 Sep 21. doi: 10.1089/thy.2022.0349.
    PubMed     Abstract available


  131. HALADA S, Baran J, Bauer AJ, Ricarte-Filho JC, et al
    Clinicopathologic Characteristics of Pediatric Follicular Variant of Papillary Thyroid Carcinoma Subtypes: A Retrospective Cohort Study.
    Thyroid. 2022 Sep 14. doi: 10.1089/thy.2022.0239.
    PubMed     Abstract available


  132. GRANI G, Lamartina L, Montesano T, Giacomelli L, et al
    Prevalence of thyroid nodules and thyroid cancer in individuals with a first-degree family history of non-medullary thyroid cancer: a cross-sectional study based on sonographic screening.
    Thyroid. 2022 Sep 13. doi: 10.1089/thy.2022.0253.
    PubMed     Abstract available


  133. QIANG J, Alwithenani R, Uleryk E, Ezzat S, et al
    Risk of Adverse Cardiovascular Outcomes in Differentiated Thyroid Cancer Survivors: A Systematic Review and Meta-analysis.
    Thyroid. 2022 Sep 8. doi: 10.1089/thy.2022.0209.
    PubMed     Abstract available


  134. BUI QA, Gunathilake M, Lee J, Lee EK, et al
    Relationship between physical activity levels and thyroid cancer risk: A prospective cohort study in Korea.
    Thyroid. 2022 Sep 7. doi: 10.1089/thy.2022.0250.
    PubMed     Abstract available


  135. SUZUKI S, Suzuki S, Iwadate M, Matsuzuka T, et al
    Possible association between thyroid nodule formation and developmental alterations in the pituitary-thyroid hormone axis in children and adolescents: The Fukushima Health Management Survey.
    Thyroid. 2022 Sep 6. doi: 10.1089/thy.2022.0327.
    PubMed     Abstract available


  136. EGAN C, Stefanova D, Thiesmeyer JW, Lee YJ, et al
    Proposed Risk Stratification and Patterns of Radioactive Iodine Therapy in Malignant Struma Ovarii.
    Thyroid. 2022;32:1101-1108.
    PubMed     Abstract available


    August 2022
  137. DIGENNARO C, Vahdat V, Jalali M, Toumi A, et al
    Assessing Bias and Limitations of Clinical Validation Studies of Molecular Diagnostic Tests for Indeterminate Thyroid Nodules: Systematic Review and Meta-Analysis.
    Thyroid. 2022 Aug 23. doi: 10.1089/thy.2022.0269.
    PubMed     Abstract available


  138. BAL C, Satapathy S, Tupalli A, Ballal S, et al
    Propensity Score Matched Outcome Analysis of Lobar Ablation versus Completion Thyroidectomy in Low-risk Differentiated Thyroid Cancer Patients: Median Follow-up of 11 Years.
    Thyroid. 2022 Aug 18. doi: 10.1089/thy.2022.0234.
    PubMed     Abstract available


  139. NIGAM A, Xu B, Spanheimer P, Ganly I, et al
    Tumor Grade Predicts for Calcitonin Doubling Times and Disease-Specific Outcomes After Resection of Medullary Thyroid Carcinoma.
    Thyroid. 2022 Aug 11. doi: 10.1089/thy.2022.0217.
    PubMed     Abstract available


  140. KIM S, Song SH, Lee CW, Kwon JT, et al
    Low-level environmental mercury exposure and thyroid cancer risk among residents living near national industrial complexes in South Korea: A population-based cohort study.
    Thyroid. 2022 Aug 11. doi: 10.1089/thy.2022.0084.
    PubMed     Abstract available


  141. BROSE M, Smit J, Lin CC, Tori M, et al
    Multi-kinase Inhibitors for the Treatment of Asymptomatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Global, Non-Interventional Study (RIFTOS MKI).
    Thyroid. 2022 Aug 11. doi: 10.1089/thy.2022.0061.
    PubMed     Abstract available


  142. KEEFE G, Culbreath K, Cherella CE, Smith JR, et al
    Autoimmune Thyroiditis and Risk of Malignancy in Children with Thyroid Nodules.
    Thyroid. 2022 Aug 11. doi: 10.1089/thy.2022.0241.
    PubMed     Abstract available


  143. KUCHARECZKO A, Kopczynski J, Kowalik A, Hincza-Nowak K, et al
    A significance of concomitant BRAFV600E and TERT mutations in Polish patients with papillary thyroid microcarcinoma - a retrospective cohort study based on 430 cases.
    Thyroid. 2022 Aug 11. doi: 10.1089/thy.2022.0155.
    PubMed     Abstract available


  144. LI C, Gao Y, Zhou P, Yue T, et al
    Comparison of the robotic bilateral axillo-breast approach and conventional open thyroidectomy in pediatric patients: a retrospective cohort study.
    Thyroid. 2022 Aug 9. doi: 10.1089/thy.2022.0242.
    PubMed     Abstract available


  145. FINKELSTEIN S, Sistrunk J, Malchoff C, Thompson DV, et al
    A Retrospective Evaluation of the Diagnostic Performance of an Interdependent Pairwise microRNA Expression Analysis with a Mutation Panel in Indeterminate Thyroid Nodules.
    Thyroid. 2022 Aug 9. doi: 10.1089/thy.2022.0124.
    PubMed     Abstract available


    July 2022
  146. JERKOVICH F, Abelleira E, Bueno F, Guerrero L, et al
    Active surveillance of small metastatic lymph nodes as an alternative to surgery in selected patients with low risk papillary thyroid cancer: A retrospective cohort study.
    Thyroid. 2022 Jul 25. doi: 10.1089/thy.2022.0302.
    PubMed     Abstract available


  147. SKAUGEN JM, Taneja C, Liu JB, Wald AI, et al
    Performance of a Multigene Genomic Classifier in Thyroid Nodules with Suspicious for Malignancy Cytology.
    Thyroid. 2022 Jul 21. doi: 10.1089/thy.2022.0282.
    PubMed     Abstract available


  148. METE O, Asa SL
    Oncologic Outcome Prediction in Differentiated Thyroid Carcinoma: Assumption or Improved Accuracy?
    Thyroid. 2022 Jul 15. doi: 10.1089/thy.2022.0379.
    PubMed     Abstract available


  149. DOOLITTLE WKL, Zhao L, Cheng SY
    Blocking CDK7-mediated NOTCH1-cMYC Signaling Attenuates Cancer Stem Cell Activity in Anaplastic Thyroid Cancer.
    Thyroid. 2022 Jul 13. doi: 10.1089/thy.2022.0087.
    PubMed     Abstract available


  150. CORSELLO A, Ramunno V, Locantore P, Pacini G, et al
    Medullary Thyroid Cancer with Ectopic Cushing's Syndrome: A Case Report and Systematic Review of Detailed Cases from the Literature.
    Thyroid. 2022 Jul 12. doi: 10.1089/thy.2021.0696.
    PubMed     Abstract available


  151. RANDOLPH GW, Sosa JA, Hao Y, Angell TE, et al
    Preoperative Identification of Medullary Thyroid Carcinoma (MTC): Clinical Validation of the Afirma MTC RNA-Sequencing Classifier.
    Thyroid. 2022 Jul 6. doi: 10.1089/thy.2022.0189.
    PubMed     Abstract available


    June 2022
  152. PLITT G, Brewer T, Yehia L, Jin J, et al
    Development and progression of thyroid disease in PTEN hamartoma tumor syndrome: refined surveillance recommendations.
    Thyroid. 2022 Jun 27. doi: 10.1089/thy.2022.0181.
    PubMed     Abstract available


  153. NOTO B, Asmus I, Schafers M, Goerlich D, et al
    Predictors of anxiety and depression in differentiated thyroid cancer survivors: Results of a cross-sectional Study.
    Thyroid. 2022 Jun 23. doi: 10.1089/thy.2022.0067.
    PubMed     Abstract available


  154. PAPACHRISTOS AJ, Do K, Tsang V, Sywak M, et al
    Outcomes of papillary thyroid microcarcinoma presenting with palpable lateral lymphadenopathy.
    Thyroid. 2022 Jun 15. doi: 10.1089/thy.2022.0109.
    PubMed     Abstract available


  155. HWANGBO Y, Choi JY, Lee EK, Ryu CH, et al
    A cross-sectional survey of patient treatment choice in a multicenter prospective cohort study on active surveillance of papillary thyroid microcarcinoma (MAeSTro).
    Thyroid. 2022 Jun 13. doi: 10.1089/thy.2021.0619.
    PubMed     Abstract available


  156. BUSAIDY N, Konda B, Wei L, Wirth LJ, et al
    Dabrafenib vs dabrafenib + trametinib in BRAF-mutated radioactive iodine refractory differentiated thyroid cancer - results of a randomized, phase 2, open-label, multicenter trial.
    Thyroid. 2022 Jun 4. doi: 10.1089/thy.2022.0115.
    PubMed     Abstract available


    May 2022
  157. WIJEWARDENE A, Gill AJ, Gild M, Learoyd DL, et al
    A retrospective cohort study with prospective validation of predictors of differentiated thyroid cancer outcomes.
    Thyroid. 2022 May 27. doi: 10.1089/thy.2021.0563.
    PubMed     Abstract available


  158. HU TX, Nguyen DT, Patel MK, Beckett K, et al
    The Effect Modification of Ultrasound Risk Classification on Molecular Testing in Predicting the Risk of Malignancy in Cytologically Indeterminate Thyroid Nodules.
    Thyroid. 2022 May 25. doi: 10.1089/thy.2021.0659.
    PubMed     Abstract available


  159. ERICKSON T, Shih YP, Fass J, Jang M, et al
    T cells engineered to express immunoreceptors targeting the frequently expressed medullary thyroid cancer antigens calcitonin, CEA and RET M918T.
    Thyroid. 2022 May 19. doi: 10.1089/thy.2022.0020.
    PubMed     Abstract available


  160. HATASHIMA A, Archambeau B, Armbruster H, Xu M, et al
    An Evaluation of Clinical Efficacy of Immune Checkpoint Inhibitors for Patients with Anaplastic Thyroid Carcinoma.
    Thyroid. 2022 May 18. doi: 10.1089/thy.2022.0073.
    PubMed     Abstract available


  161. KIM K, Choi JY, Kim SJ, Lee EK, et al
    Active Surveillance Versus Immediate Surgery for Low-Risk Papillary Thyroid Microcarcinoma Patients in South Korea: A Cost-Minimization Analysis from the MAeSTro Study.
    Thyroid. 2022 May 16. doi: 10.1089/thy.2021.0679.
    PubMed     Abstract available


  162. YI W, Kim BH, Kim M, Kim J, et al
    Heart failure and stroke risks in users of liothyronine with or without levothyroxine compared to levothyroxine alone: A propensity score matched analysis.
    Thyroid. 2022 May 16. doi: 10.1089/thy.2021.0634.
    PubMed     Abstract available


  163. SORENSEN JR, Dossing H, Watt T, Cramon PK, et al
    The effect of laser thermal ablation on quality of life: Improvements in patients with solid-cystic thyroid nodules.
    Thyroid. 2022 May 16. doi: 10.1089/thy.2021.0665.
    PubMed     Abstract available


  164. LEE NY, Riaz N, Wu V, Brinkman T, et al
    A Pilot Study of Durvalumab (MEDI4736) with Tremelimumab in Combination with Image Guided Stereotactic Body Radiotherapy (SBRT) in the Treatment of Metastatic Anaplastic Thyroid Cancer.
    Thyroid. 2022 May 6. doi: 10.1089/thy.2022.0050.
    PubMed     Abstract available


    April 2022
  165. TOFT DJ, Schneider AB
    PROTECTING THE THYROID IN TIMES OF CONFLICT (UKRAINE 2022).
    Thyroid. 2022 Apr 25. doi: 10.1089/thy.2022.0135.
    PubMed     Abstract available


  166. SORENSEN SM, De la Cour CD, Maltesen T, Urbute A, et al
    Temporal trends in papillary and follicular thyroid cancer incidence from 1995 to 2019 in adults in Denmark according to education and income.
    Thyroid. 2022 Apr 22. doi: 10.1089/thy.2021.0602.
    PubMed     Abstract available


  167. KIM M, Jin M, Jeon MJ, Kim EY, et al
    Lenvatinib compared with sorafenib as a first-line treatment for radioactive iodinerefractory, progressive, differentiated thyroid carcinoma: Real-world outcomes in a multicenter retrospective cohort study.
    Thyroid. 2022 Apr 20. doi: 10.1089/thy.2022.0054.
    PubMed     Abstract available


  168. WEI J, Thwin M, Nickel B, Glover AR, et al
    Factors which inform individual decision making between active surveillance, hemithyroidectomy and total thyroidectomy for low-risk thyroid cancer: A scoping review.
    Thyroid. 2022 Apr 19. doi: 10.1089/thy.2021.0646.
    PubMed     Abstract available


  169. CHOU R, Dana T, Brent GA, Goldner W, et al
    Serum Thyroglobulin Measurement Following Surgery without Radioactive Iodine for Differentiated Thyroid Cancer: A Systematic Review.
    Thyroid. 2022 Apr 12. doi: 10.1089/thy.2021.0666.
    PubMed     Abstract available


  170. CAPDEVILA J, Klochikhin A, Leboulleux S, Isaev P, et al
    A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg per Day Compared with the Cabozantinib Capsule at 140 mg per Day in Patients With Progressive, Metastatic Medullary Thyroid Cancer.
    Thyroid. 2022 Apr 10. doi: 10.1089/thy.2022.0027.
    PubMed     Abstract available


    March 2022
  171. WANG Z, Tang C, Wang Y, Yin Z, et al
    Inclusion of the Number of Metastatic Lymph Nodes in the Staging System for Medullary Thyroid Cancer: Validating a Modified AJCC TNM Staging System.
    Thyroid. 2022 Mar 30. doi: 10.1089/thy.2021.0571.
    PubMed     Abstract available


  172. ZHANG F, Teng D, Tong N, Wang G, et al
    Gender-Specific Associations Between Metabolic Disorders and Thyroid Nodules: A Cross-Sectional Population-Based Study From China.
    Thyroid. 2022 Mar 23. doi: 10.1089/thy.2021.0686.
    PubMed     Abstract available


  173. MA LX, Espin-Garcia O, Bedard PL, Stockley TL, et al
    Clinical Application of Next-Generation Sequencing in Advanced Thyroid Cancers.
    Thyroid. 2022 Mar 9. doi: 10.1089/thy.2021.0542.
    PubMed     Abstract available


  174. YEO Y, Shin DW, Han K, Kim D, et al
    Smoking, alcohol consumption, and the risk of thyroid cancer: a population-based Korean cohort study of 10 million people.
    Thyroid. 2022 Mar 2. doi: 10.1089/thy.2021.0675.
    PubMed     Abstract available


  175. MURI R, Trippel M, Borner U, Weidner SE, et al
    The impact of rapid on-site evaluation (ROSE) on the quality and diagnostic value of thyroid nodule fine-needle aspirations.
    Thyroid. 2022 Mar 2. doi: 10.1089/thy.2021.0551.
    PubMed     Abstract available


  176. MATSUURA D, Yuan A, Wang L, Ranganath R, et al
    Follicular and Hurthle Cell Carcinoma: Comparison of Clinicopathological Features and Clinical Outcomes.
    Thyroid. 2022;32:245-254.
    PubMed     Abstract available


  177. SIMOES-PEREIRA J, C Ferreira T, Limbert E, Cavaco BM, et al
    Response to "Radioiodine Is Molecular Radiotherapy Governed by Predictable Deterministic Radiobiology Expressed in Gray, Not Millicuries" by Kao.
    Thyroid. 2022;32:342-343.
    PubMed    


  178. KAO YH
    Letter to the Editor: Radioiodine Is Molecular Radiotherapy Governed by Predictable Deterministic Radiobiology Expressed in Gray, Not Millicuries.
    Thyroid. 2022;32:340-341.
    PubMed    


  179. SUZUKI N, Watanabe N, Noh JY, Yoshimura R, et al
    The relationship between primary thyroid lymphoma and various types of thyroid autoimmunity: A retrospective cohort study of 498 cases, including 9 cases with Graves' disease.
    Thyroid. 2022 Mar 1. doi: 10.1089/thy.2021.0613.
    PubMed     Abstract available


  180. HOANG JK, Asadollahi S, Durante C, Hegedus L, et al
    An International Survey on Utilization of Five Thyroid Nodule Risk Stratification Systems: A Needs Assessment with Future Implications.
    Thyroid. 2022 Mar 1. doi: 10.1089/thy.2021.0558.
    PubMed     Abstract available


  181. BLOMAIN ES, Berta S, Hug NF, Giao DM, et al
    Radiotherapy for brain metastases from thyroid cancer: an institutional and national retrospective cohort study.
    Thyroid. 2022 Mar 1. doi: 10.1089/thy.2021.0628.
    PubMed     Abstract available


    February 2022
  182. HSIAO V, Arroyo N, Fernandes-Taylor S, Chiu AS, et al
    Sensitivity of Palpation for Detection of Thyroid Nodules with Attention to Size.
    Thyroid. 2022 Feb 25. doi: 10.1089/thy.2021.0692.
    PubMed     Abstract available


  183. JONKLAAS J
    Impact of Nasolacrimal Dysfunction in Thyroid Cancer Survivors.
    Thyroid. 2022 Feb 18. doi: 10.1089/thy.2022.0095.
    PubMed     Abstract available


  184. GROUSSIN L, Theodon H, Bessiene L, Bricaire L, et al
    Redifferentiating effect of larotrectinib in NTRK-rearranged advanced radioactive-iodine refractory thyroid cancer.
    Thyroid. 2022 Feb 16. doi: 10.1089/thy.2021.0524.
    PubMed     Abstract available


  185. MEGWALU U, Moon PK
    Thyroid Cancer Incidence and Mortality Trends in the United States: 2000 - 2018.
    Thyroid. 2022 Feb 8. doi: 10.1089/thy.2021.0662.
    PubMed     Abstract available


    January 2022
  186. CHOU R, Dana T, Haymart MR, Leung AM, et al
    Active surveillance versus thyroid surgery for differentiated thyroid cancer: A systematic review.
    Thyroid. 2022 Jan 26. doi: 10.1089/thy.2021.0539.
    PubMed     Abstract available


  187. PASQUAL E, Sosa JA, Chen Y, Schonfeld SJ, et al
    Trends in the management of localized papillary thyroid cancer in the United States (2000-2018).
    Thyroid. 2022 Jan 25. doi: 10.1089/thy.2021.0557.
    PubMed     Abstract available


  188. TCHEKMEDYIAN V, Dunn L, Sherman EJ, Baxi SS, et al
    Enhancing Radioiodine Incorporation in BRAF-Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial.
    Thyroid. 2022 Jan 19. doi: 10.1089/thy.2021.0565.
    PubMed     Abstract available


  189. STAGNARO-GREEN A
    Thyroid Disease in Pregnancy: A Touch of Clarity.
    Thyroid. 2022 Jan 12. doi: 10.1089/thy.2021.0668.
    PubMed     Abstract available


  190. SAWKA AM, Ghai S, Rotstein L, Irish JC, et al
    A quantitative analysis examining patients' choice of active surveillance or surgery for managing low risk papillary thyroid cancer.
    Thyroid. 2022 Jan 12. doi: 10.1089/thy.2021.0485.
    PubMed     Abstract available


  191. PIERANNUNZIO D, Fedeli U, Francisci S, De Paoli A, et al
    Thyroidectomies in Italy: A population-based national analysis from 2001 to 2018.
    Thyroid. 2022 Jan 12. doi: 10.1089/thy.2021.0531.
    PubMed     Abstract available


    December 2021
  192. SHOBAB L, Burman KD, Wartofsky L
    Sex Differences in Differentiated Thyroid Cancer.
    Thyroid. 2021 Dec 31. doi: 10.1089/thy.2021.0361.
    PubMed     Abstract available


  193. HESS J, Newbern DK, Beebe KL, Walsh AM, et al
    High prevalence of gene fusions and copy number alterations in pediatric radiation therapy-induced papillary and follicular thyroid carcinomas.
    Thyroid. 2021 Dec 16. doi: 10.1089/thy.2021.0217.
    PubMed     Abstract available


  194. SHIN A, Cho S, Jang D, Abe SK, et al
    Body mass index and thyroid cancer risk - A pooled analysis of half a million men and women in the Asia Cohort Consortium.
    Thyroid. 2021 Dec 16. doi: 10.1089/thy.2021.0445.
    PubMed     Abstract available


  195. MEHTA V, Naraparaju A, Liao D, Davies L, et al
    What's in a Name? A Cost-Effectiveness Analysis of the Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP) Nomenclature Revision.
    Thyroid. 2021 Dec 16. doi: 10.1089/thy.2021.0486.
    PubMed     Abstract available


  196. MOLLEN K, Shaffer AD, Yip L, Monaco S, et al
    Unique Molecular Signatures are Associated with Aggressive Histology in Pediatric Differentiated Thyroid Cancer.
    Thyroid. 2021 Dec 16. doi: 10.1089/thy.2021.0317.
    PubMed     Abstract available


  197. LIWEN L, Xinguang Q
    Safety and efficacy of ultrasound-guided radiofrequency ablation for benign nonfunctional thyroid nodules in children: a retrospective study of 62 patients with over 4 years of follow-up.
    Thyroid. 2021 Dec 16. doi: 10.1089/thy.2021.0454.
    PubMed     Abstract available


  198. LEE JY, Woo KI
    Surgical risk prediction for nasolacrimal duct obstruction in radioactive iodine treated thyroid cancer: A nationwide cohort study.
    Thyroid. 2021 Dec 12. doi: 10.1089/thy.2021.0418.
    PubMed     Abstract available


  199. MATSUURA D, Yuan A, Harries V, Shaha AR MD, et al
    Surgical Management of Low-/Intermediate-Risk Node Negative Thyroid Cancer: A Single-Institution Study Using Propensity Matching Analysis to Compare Thyroid Lobectomy and Total Thyroidectomy.
    Thyroid. 2021 Dec 3. doi: 10.1089/thy.2021.0356.
    PubMed     Abstract available


    November 2021
  200. BISCHOFF L, Haymart MR
    Optimal TSH following lobectomy for papillary thyroid cancer: Does it exist?
    Thyroid. 2021 Nov 22. doi: 10.1089/thy.2021.0617.
    PubMed     Abstract available


  201. DI CRISTOFANO A
    The Year in Basic Thyroid Cancer Research.
    Thyroid. 2021 Nov 22. doi: 10.1089/thy.2021.0561.
    PubMed     Abstract available


  202. HAYMART MR
    Year in Thyroidology- Recent Developments and Future Challenges: Clinical Science Review.
    Thyroid. 2021 Nov 22. doi: 10.1089/thy.2021.0562.
    PubMed     Abstract available


  203. JONGEJAN RMS, van Velsen EFS, Meima ME, Klein T, et al
    Change in Thyroid Hormone Metabolite concentrations across Different Thyroid States.
    Thyroid. 2021 Nov 22. doi: 10.1089/thy.2021.0453.
    PubMed     Abstract available


  204. ROBENSHTOK E, Neeman B, Reches L, Ritter A, et al
    Adverse Histological Features of Differentiated Thyroid Cancer are Commonly Found in Autopsy Studies: Implications for Treatment Guidelines.
    Thyroid. 2021 Nov 13. doi: 10.1089/thy.2021.0268.
    PubMed     Abstract available


  205. SHIMURA H, Matsuzuka T, Suzuki S, Iwadate M, et al
    Fine Needle Aspiration Cytology Implementation and Malignancy Rates in Children and Adolescents Based on Japanese Guidelines: The Fukushima Health Management Survey.
    Thyroid. 2021;31:1683-1692.
    PubMed     Abstract available


    October 2021
  206. BARAN J, Bauer AJ, Halada SJ, Mostoufi-Moab S, et al
    Clinical Course of Early Postoperative Hypothyroidism Following Thyroid Lobectomy in Pediatrics.
    Thyroid. 2021 Oct 29. doi: 10.1089/thy.2021.0396.
    PubMed     Abstract available


  207. NEWMAN SK, Harries V, Wang LY, McGill MR, et al
    Invasion of a Recurrent Laryngeal Nerve from Small, Well-Differentiated Papillary Thyroid Cancers: Patient Selection Implications for Active Surveillance.
    Thyroid. 2021 Oct 29. doi: 10.1089/thy.2021.0310.
    PubMed     Abstract available


  208. MONTI S, Presciuttini F, Deiana MG, Motta C, et al
    Cortisol deficiency in Lenvatinib treatment of thyroid cancer: an underestimated, common adverse event.
    Thyroid. 2021 Oct 19. doi: 10.1089/thy.2021.0040.
    PubMed     Abstract available


  209. BERTOL BC, Bales ES, Calhoun JD, Mayberry A, et al
    Lenvatinib plus Anti-PD-1 Combination Therapy for Advanced Cancers: Defining Mechanisms of Resistance in an Inducible Transgenic Model of Thyroid Cancer.
    Thyroid. 2021 Oct 12. doi: 10.1089/thy.2021.0371.
    PubMed     Abstract available


  210. PITT SC, Saucke MC, Roman BR, Alexander SC, et al
    The Influence of Emotions on Treatment Decisions about Low-Risk Thyroid Cancer: A Qualitative Study.
    Thyroid. 2021 Oct 12. doi: 10.1089/thy.2021.0323.
    PubMed     Abstract available


  211. BALLAL S, Yadav MP, Moon ES, Roesch F, et al
    Novel Fibroblast Activation Protein Inhibitor-Based targeted Theranostics for Radioiodine Refractory differentiated Thyroid Cancer Patients: A Pilot Study.
    Thyroid. 2021 Oct 12. doi: 10.1089/thy.2021.0412.
    PubMed     Abstract available


  212. XU S, Huang Y, Huang H, Zhang X, et al
    Optimal serum thyroid-stimulating hormone level for patients with papillary thyroid carcinoma after lobectomy.
    Thyroid. 2021 Oct 7. doi: 10.1089/thy.2021.0404.
    PubMed     Abstract available


  213. HUANG NS, Wei WJ, Xiang J, Chen JY, et al
    The Efficacy and Safety of Anlotinib in Neoadjuvant Treatment of Locally Advanced Thyroid Cancer: A Single-arm Phase II Clinical Trial.
    Thyroid. 2021 Oct 6. doi: 10.1089/thy.2021.0307.
    PubMed     Abstract available


  214. RANA C, Vuong HG, Nguyen TQ, Nguyen HC, et al
    The Incidence of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features: A Meta-Analysis Assessing Worldwide Impact of the Reclassification.
    Thyroid. 2021;31:1502-1513.
    PubMed     Abstract available


    September 2021
  215. SUGINO K, Nagahama M, Kitagawa W, Ohkuwa K, et al
    Cutoff age between pediatric and adult thyroid differentiated cancer: Is 18 years old appropriate?
    Thyroid. 2021 Sep 22. doi: 10.1089/thy.2021.0255.
    PubMed     Abstract available


  216. FORLEO R, Grani G, Alfo M, Zilioli V, et al
    Minimal Extrathyroidal Extension in Predicting 1-Year Outcomes: A Longitudinal Multicenter Study of Low-to-Intermediate-Risk Papillary Thyroid Carcinoma (ITCO#4).
    Thyroid. 2021 Sep 19. doi: 10.1089/thy.2021.0248.
    PubMed     Abstract available


  217. SATO A, Tanabe M, Tsuboi Y, Niwa T, et al
    Circulating tumor DNA harboring the BRAF V600E mutation may predict poor outcomes of primary papillary thyroid cancer patients.
    Thyroid. 2021 Sep 19. doi: 10.1089/thy.2021.0267.
    PubMed     Abstract available


  218. DEKKER BL, Muller Kobold AC, Brouwers AH, Williams GRR, et al
    Bone Mineral Density in Adult Survivors of Pediatric Differentiated Thyroid Carcinoma: a longitudinal follow-up study.
    Thyroid. 2021 Sep 13. doi: 10.1089/thy.2021.0179.
    PubMed     Abstract available


  219. GUO K, Qian K, Shi Y, Sun T, et al
    Clinical and Molecular Characterizations of Papillary Thyroid Cancer in Children and Young Adults: a Multicenter Retrospective Study.
    Thyroid. 2021 Sep 13. doi: 10.1089/thy.2021.0003.
    PubMed     Abstract available


  220. TESSLER FN
    American Thyroid Association Non-Classifiable Thyroid Nodules: A New Perspective.
    Thyroid. 2021 Sep 2. doi: 10.1089/thy.2021.0449.
    PubMed     Abstract available


  221. MA T, Semsarian CR, Barratt A, Parker L, et al
    Rethinking low risk micropapillary thyroid cancer: an evidence review for recalibrating diagnostic thresholds and/or alternative labels.
    Thyroid. 2021 Sep 2. doi: 10.1089/thy.2021.0274.
    PubMed     Abstract available


  222. HO AS, Luu M, Shafqat I, Mallen-St Clair J, et al
    Predictive impact of metastatic lymph node burden on distant metastasis across papillary thyroid cancer variants.
    Thyroid. 2021 Sep 2. doi: 10.1089/thy.2021.0131.
    PubMed     Abstract available


    August 2021
  223. KIM HJ, Chung SM, Kim H, Jang JY, et al
    Long-term efficacy of ultrasound-guided laser ablation for papillary thyroid microcarcinoma: Results of a 10-year retrospective study.
    Thyroid. 2021 Aug 27. doi: 10.1089/thy.2021.0151.
    PubMed     Abstract available


  224. KOEHLER VF, Berg E, Adam P, Weber GL, et al
    Real world efficacy and safety of multi-tyrosine kinase inhibitors in radioiodine refractory thyroid cancer.
    Thyroid. 2021 Aug 18. doi: 10.1089/thy.2021.0091.
    PubMed     Abstract available


  225. GROUSSIN L, Bessiene L, Arrondeau J, Garinet S, et al
    Selpercatinib-Enhanced Radioiodine Uptake in RET-Rearranged Thyroid Cancer.
    Thyroid. 2021 Aug 18. doi: 10.1089/thy.2021.0144.
    PubMed     Abstract available


  226. XU S, Huang H, Zhang X, Huang Y, et al
    Predictive value of serum thyroglobulin for structural recurrence following lobectomy for papillary thyroid carcinoma.
    Thyroid. 2021 Aug 3. doi: 10.1089/thy.2021.0209.
    PubMed     Abstract available


  227. FIGGE JJ, Gooding WE, Steward DL, Yip L, et al
    Do Ultrasound Patterns and Clinical Parameters Inform the Probability of Thyroid Cancer Predicted by Molecular Testing in Nodules with Indeterminate Cytology?
    Thyroid. 2021 Aug 3. doi: 10.1089/thy.2021.0119.
    PubMed     Abstract available


  228. PIEK MW, de Boer JP, Vriens MR, van Leeuwaarde RS, et al
    Retrospective analyses of 18FDG-PET/CT thyroid incidentaloma in adults: incidence, treatment and outcome in a tertiary cancer referral center.
    Thyroid. 2021 Aug 3. doi: 10.1089/thy.2021.0226.
    PubMed     Abstract available


    July 2021
  229. KOBALY K, Kim CS, Langer JE, Mandel SJ, et al
    Macrocalcifications Do Not Alter Malignancy Risk Within the American Thyroid Association Sonographic Pattern System When Present in Non-High Suspicion Thyroid Nodules.
    Thyroid. 2021 Jul 27. doi: 10.1089/thy.2021.0140.
    PubMed     Abstract available


  230. OKAZAKI-HADA M, Maruoka A, Yamamoto M, Ito M, et al
    Poorly differentiated thyroid carcinoma coexisting with Graves' disease involving T3 thyrotoxicosis due to increased D1 and D2 activities.
    Thyroid. 2021 Jul 18. doi: 10.1089/thy.2021.0082.
    PubMed     Abstract available


  231. YAN L, Zhang M, Song Q, Luo Y, et al
    Ultrasound-Guided Radiofrequency Ablation Versus Thyroid Lobectomy for Low-Risk Papillary Thyroid Microcarcinoma: A Propensity-matched Cohort Study of 884 Patients.
    Thyroid. 2021 Jul 16. doi: 10.1089/thy.2021.0100.
    PubMed     Abstract available


  232. JIN M, Kim HI, Ha J, Jeon MJ, et al
    Tumor Volume Doubling Time in Active Surveillance of Papillary Thyroid Microcarcinoma: A Multicenter Cohort Study in Korea.
    Thyroid. 2021 Jul 6. doi: 10.1089/thy.2021.0094.
    PubMed     Abstract available


    June 2021
  233. SIMOES-PEREIRA J, C Ferreira T, Limbert E, Cavaco BM, et al
    Outcomes of thyrotropin alfa vs. levothyroxine withdrawal-aided radioiodine therapy for distant metastasis of papillary thyroid cancer.
    Thyroid. 2021 Jun 22. doi: 10.1089/thy.2021.0013.
    PubMed     Abstract available


  234. RYDER M, Wentworth M, Algeciras-Schimnich A, Morris JC 3rd, et al
    Blocking the TSH receptor with K1-70 in a patient with follicular thyroid cancer, Graves' disease and Graves' ophthalmopathy.
    Thyroid. 2021 Jun 11. doi: 10.1089/thy.2021.0053.
    PubMed     Abstract available


  235. GRONLUND MP, Schmidt Jensen J, Hahn CH, Gronhoj C, et al
    Risk factors for recurrence of follicular thyroid cancer: A systematic review.
    Thyroid. 2021 Jun 9. doi: 10.1089/thy.2020.0921.
    PubMed     Abstract available


  236. EGAN CE, Stefanova D, Ahmed A, Raja VJ, et al
    CSPG4 is a Potential Therapeutic Target in Anaplastic Thyroid Cancer.
    Thyroid. 2021 Jun 3. doi: 10.1089/thy.2021.0067.
    PubMed     Abstract available


    May 2021
  237. BUNEVICIUS A, Fribance S, Pikis S, Lee JYK, et al
    Stereotactic Radiosurgery for Differentiated Thyroid Cancer Brain Metastases: An International, Multicenter Study.
    Thyroid. 2021 May 11. doi: 10.1089/thy.2020.0947.
    PubMed     Abstract available


    April 2021
  238. KIM DH, Kim SW, Kang P, Choi J, et al
    Near-infrared autofluorescence imaging may reduce temporary hypoparathyroidism in patients undergoing total thyroidectomy and central neck dissection.
    Thyroid. 2021 Apr 28. doi: 10.1089/thy.2021.0056.
    PubMed     Abstract available


  239. MARQUES IJ, Gomes I, Pojo M, Pires C, et al
    Identification of SPRY4 as a novel candidate susceptibility gene for familial non-medullary thyroid cancer.
    Thyroid. 2021 Apr 28. doi: 10.1089/thy.2020.0290.
    PubMed     Abstract available


  240. LUBITZ CC, Sadow PM, Daniels GH, Wirth LJ, et al
    Progress in Treating Advanced Thyroid Cancers in the Era of Targeted Therapy.
    Thyroid. 2021 Apr 16. doi: 10.1089/thy.2020.0962.
    PubMed     Abstract available


  241. VUONG HG, Jung CK, Kakudo K, Bychkov A, et al
    Response to Cherella et al. re: "The use of The Bethesda System for Reporting Thyroid Cytopathology in Pediatric Thyroid Nodules: a meta-analysis".
    Thyroid. 2021 Apr 15. doi: 10.1089/thy.2021.0190.
    PubMed     Abstract available


  242. LEE SB, Cho YJ, Lee S, Choi YH, et al
    Korean Society of Thyroid Radiology (KSThR) guidelines for the management of pediatric thyroid nodules: Suitability and risk factors.
    Thyroid. 2021 Apr 9. doi: 10.1089/thy.2020.0875.
    PubMed     Abstract available


  243. CHERELLA CE, Cibas ES, Wassner AJ
    Re: "The use of the Bethesda System for Reporting Thyroid Cytopathology in pediatric thyroid nodules - A meta-analysis" by Vuong, et al.
    Thyroid. 2021 Apr 5. doi: 10.1089/thy.2021.0116.
    PubMed     Abstract available


  244. NISHINO M, Mateo R, Kilim H, Feldman A, et al
    Repeat Fine Needle Aspiration Cytology Refines the Selection of Thyroid Nodules for Afirma Gene Expression Classifier Testing.
    Thyroid. 2021 Apr 3. doi: 10.1089/thy.2020.0969.
    PubMed     Abstract available


  245. KAYA C, Dorsaint P, Mercurio S, Campbell AM, et al
    Limitations of Detecting Genetic Variants from the RNA Sequencing Data in Tissue and Fine-Needle Aspiration Samples.
    Thyroid. 2021;31:589-595.
    PubMed     Abstract available


  246. GULEC SA, Ahuja S, Avram A, Bernet V, et al
    A JOINT STATEMENT FROM THE AMERICAN THYROID ASSOCIATION, THE EUROPEAN ASSOCIATION OF NUCLEAR MEDICINE, THE EUROPEAN THYROID ASSOCIATION, THE SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING ON CURRENT DIAGNOSTIC AND THERANOSTIC APPROACHES IN THE MANA
    Thyroid. 2021 Apr 1. doi: 10.1089/thy.2020.0826.
    PubMed     Abstract available


    March 2021
  247. PAPALEONTIOU M, Chen D, Banerjee M, Reyes-Gastelum D, et al
    TSH Suppression for Papillary Thyroid Cancer: A Physician Survey Study.
    Thyroid. 2021 Mar 27. doi: 10.1089/thy.2021.0033.
    PubMed     Abstract available


  248. GORTAKOWSKI M, Feghali K, Osakwe IN
    SINGLE INSTITUTION EXPERIENCE WITH AFIRMA AND THYROSEQ TESTING IN INDETERMINATE THYROID NODULES.
    Thyroid. 2021 Mar 25. doi: 10.1089/thy.2020.0801.
    PubMed     Abstract available


  249. PAPALEONTIOU M, Norton EC, Reyes-Gastelum D, Banerjee M, et al
    Competing Causes of Death in Older Adults with Thyroid Cancer.
    Thyroid. 2021 Mar 25. doi: 10.1089/thy.2020.0929.
    PubMed     Abstract available


  250. BIBLE KC, Kebebew E, Brierley J, Brito JP, et al
    2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer.
    Thyroid. 2021;31:337-386.
    PubMed     Abstract available


    February 2021
  251. TAYLOR MH, Takahashi S, Capdevila J, Tahara M, et al
    Correlation of Performance Status and Neutrophil-Lymphocyte Ratio With Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated With Lenvatinib.
    Thyroid. 2021 Feb 26. doi: 10.1089/thy.2020.0779.
    PubMed     Abstract available


  252. MATHEW A, Latteyer S, Frank-Raue K, Moeller LC, et al
    A Novel Double RET E768D/L790F Mutation Associated with a MEN2B-Like Phenotype.
    Thyroid. 2021;31:327-329.
    PubMed     Abstract available


  253. GRANI G, Zatelli MC, Alfo M, Montesano T, et al
    Real-World Performance of the American Thyroid Association Risk Estimates in Predicting 1-Year Differentiated Thyroid Cancer Outcomes: A Prospective Multicenter Study of 2000 Patients.
    Thyroid. 2021;31:264-271.
    PubMed     Abstract available


    January 2021
  254. VUONG HGG, Chung DGB, Ngo LM, Bui TQ, et al
    The use of the Bethesda system for reporting thyroid cytopathology in pediatric thyroid nodules - A meta-analysis.
    Thyroid. 2021 Jan 27. doi: 10.1089/thy.2020.0702.
    PubMed     Abstract available


  255. VAN VELSEN EFS, Visser WE, Stegenga MT, Maeder U, et al
    Finding the Optimal Age Cutoff for the UICC/AJCC TNM Staging System in Patients with Papillary or Follicular Thyroid Cancer.
    Thyroid. 2021 Jan 23. doi: 10.1089/thy.2020.0615.
    PubMed     Abstract available


  256. MORARIU EM, McCoy KL, Chiosea SI, Nikitski AV, et al
    Clinicopathologic Characteristics of Thyroid Nodules Positive for the THADA-IGF2BP3 Fusion on Preoperative Molecular Analysis.
    Thyroid. 2021 Jan 23. doi: 10.1089/thy.2020.0589.
    PubMed     Abstract available


  257. LONCAR I, van Dijk SPJ, Metman MJH, Lin JF, et al
    Active surveillance for papillary thyroid microcarcinoma in a population with restrictive diagnostic work-up strategies.
    Thyroid. 2021 Jan 11. doi: 10.1089/thy.2020.0845.
    PubMed     Abstract available


    December 2020
  258. CONDELLO V, Nikitski AV, Foulkes W, Nikiforov YE, et al
    Prevalence of WWP1 Gene Mutations in Patients with Thyroid Nodules.
    Thyroid. 2020 Dec 29. doi: 10.1089/thy.2020.0919.
    PubMed     Abstract available


  259. NG DL, van Zante A, Griffin A, Hills NK, et al
    A large thyroid fine needle aspiration biopsy cohort with long-term population-based follow-up.
    Thyroid. 2020 Dec 28. doi: 10.1089/thy.2020.0689.
    PubMed     Abstract available


  260. CHUNG SR, Choi YJ, Lee SS, Kim SO, et al
    Interobserver Reproducibility in Sonographic Measurement of Diameter and Volume of Papillary Thyroid Microcarinoma.
    Thyroid. 2020 Dec 7. doi: 10.1089/thy.2020.0317.
    PubMed     Abstract available


  261. TOUMI A, DiGennaro C, Vahdat V, Jalali M, et al
    Trends in Thyroid Surgery and Guideline-Concordant Care in the United States, 2007-2018.
    Thyroid. 2020 Dec 5. doi: 10.1089/thy.2020.0643.
    PubMed     Abstract available


    November 2020
  262. KANG YE, Kim JM, Lim MA, Lee SE, et al
    Growth differentiation factor 15 is a cancer cell-induced mitokine that primes thyroid cancer cells for invasiveness.
    Thyroid. 2020 Nov 30. doi: 10.1089/thy.2020.0034.
    PubMed     Abstract available


  263. SHIH P, Nickel B, Degeling C, Thomas R, et al
    Terminology change for small low-risk papillary thyroid cancer as a response to overtreatment: Results from three Australian community juries.
    Thyroid. 2020 Nov 25. doi: 10.1089/thy.2020.0694.
    PubMed     Abstract available


  264. LORUSSO L, Romei C, Piaggi P, Fustini C, et al
    Ca19.9 positivity and doubling time are prognostic factors of mortality in patients with advanced medullary thyroid cancer with no evidence of structural disease progression according to RECIST.
    Thyroid. 2020 Nov 24. doi: 10.1089/thy.2020.0060.
    PubMed     Abstract available


  265. LANDA I
    PLEKHS1 mutations in thyroid cancers.
    Thyroid. 2020 Nov 15. doi: 10.1089/thy.2020.0728.
    PubMed     Abstract available


  266. CIAPPUCCINI R, Licaj I, Lasne-Cardon A, Babin E, et al
    18F-Fluorocholine PET/CT is a highly sensitive but poorly specific tool for identifying malignancy in thyroid nodules with indeterminate cytology: The Chocolate study.
    Thyroid. 2020 Nov 12. doi: 10.1089/thy.2020.0555.
    PubMed     Abstract available


  267. RAMIREZ-MOYA J, Santisteban P
    A positive feedback loop between DICER1 and differentiation transcription factors is important for thyroid tumorigenesis.
    Thyroid. 2020 Nov 11. doi: 10.1089/thy.2020.0297.
    PubMed     Abstract available


  268. LARCHER DE ALMEIDA AM, Delfim RLC, Vidal APA, Chaves MCDACM, et al
    Combining the American Thyroid Association's ultrasound classification with cytological subcategorization improves the assessment of malignancy risk in indeterminate thyroid nodules.
    Thyroid. 2020 Nov 4. doi: 10.1089/thy.2019.0575.
    PubMed     Abstract available


  269. GUO J, Teng D, Shi X, Li Y, et al
    Exposure to the Chinese Great Famine in early life and thyroid function and disorders in adulthood: a cross-sectional study.
    Thyroid. 2020 Nov 2. doi: 10.1089/thy.2020.0325.
    PubMed     Abstract available


    October 2020
  270. JANMOHAMED N, Segal P, Corrado A, Lofters A, et al
    Endocrinologist perceived factors affecting the transition of thyroid cancer patients from specialist to primary care post-cancer treatment in Ontario, Canada.
    Thyroid. 2020 Oct 29. doi: 10.1089/thy.2020.0413.
    PubMed     Abstract available


  271. LEE YA, Yun HR, Lee J, Moon H, et al
    Trends in Pediatric Thyroid Cancer Incidence, Treatment, and Clinical Course in Korea during 2004-2016: A Nationwide Population-Based Study.
    Thyroid. 2020 Oct 27. doi: 10.1089/thy.2020.0155.
    PubMed     Abstract available


  272. SUGITANI I, Ito Y, Takeuchi D, Nakayama H, et al
    Indications and strategy for active surveillance of adult low-risk papillary thyroid microcarcinoma: consensus statements from the Japan Association of Endocrine Surgery task force on management for papillary thyroid microcarcinoma.
    Thyroid. 2020 Oct 6. doi: 10.1089/thy.2020.0330.
    PubMed     Abstract available


  273. PITT SC, Saucke MC, Wendt EM, Schneider DF, et al
    Patients' Reaction to Diagnosis with Thyroid Cancer or an Indeterminate Thyroid Nodule.
    Thyroid. 2020 Oct 3. doi: 10.1089/thy.2020.0233.
    PubMed     Abstract available


  274. PIEK MW, Postma EL, van Leeuwaarde R, de Boer JP, et al
    The effect of radioactive iodine therapy on ovarian function and fertility in female thyroid cancer patients: a systematic review and meta-analysis.
    Thyroid. 2020 Oct 3. doi: 10.1089/thy.2020.0356.
    PubMed     Abstract available


  275. TRAVERSI F, Stooss A, Dettmer MS, Charles RP, et al
    BRAFV600E overrides NOTCH signaling in thyroid cancer.
    Thyroid. 2020 Oct 3. doi: 10.1089/thy.2019.0595.
    PubMed     Abstract available


    September 2020
  276. GIANI C, Valerio L, Bongiovanni A, Durante C, et al
    Safety and quality of life data from an Italian expanded access program of lenvatinib for treatment of thyroid cancer.
    Thyroid. 2020 Sep 10. doi: 10.1089/thy.2020.0276.
    PubMed     Abstract available


  277. DEZIEL N, Zhang Y, Wang R, Wiemels J, et al
    Birth Characteristics and Risk of Pediatric Thyroid Cancer: A Population-Based Record-Linkage Study in California.
    Thyroid. 2020 Sep 10. doi: 10.1089/thy.2020.0217.
    PubMed     Abstract available


  278. YANSONG L, Yang H, Ding Y, Cheng Y, et al
    Donafenib in progressive locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer: results of a randomized, multicenter, phase II trial.
    Thyroid. 2020 Sep 10. doi: 10.1089/thy.2020.0235.
    PubMed     Abstract available


    August 2020
  279. CHEN D, Reyes-Gastelum D, Veenstra CM, Hamilton AS, et al
    Financial hardship among Hispanic women with thyroid cancer.
    Thyroid. 2020 Aug 25. doi: 10.1089/thy.2020.0497.
    PubMed     Abstract available


  280. JACOBS D, Breen CT, Pucar D, Holt E, et al
    Changes in Population-Level and Institutional-Level Prescribing Habits of Radioiodine Therapy for Papillary Thyroid Cancer.
    Thyroid. 2020 Aug 18. doi: 10.1089/thy.2020.0237.
    PubMed     Abstract available


  281. SHIN HS, Sun HJ, Whang YM, Park YJ, et al
    Metformin reduces thyroid cancer tumor growth in the metastatic niche of bone by inhibiting osteoblastic RANKL productions.
    Thyroid. 2020 Aug 13. doi: 10.1089/thy.2019.0851.
    PubMed     Abstract available


  282. ZHAO CK, Ren TT, Yin YF, Shi H, et al
    A Comparative Analysis of Two Machine Learning-based Diagnostic Patterns with ACR TI-RADS for Thyroid Nodules: Diagnostic Performance and Unnecessary Biopsy Rate.
    Thyroid. 2020 Aug 11. doi: 10.1089/thy.2020.0305.
    PubMed     Abstract available


  283. KOEHLER V, Adam P, Frank-Raue K, Raue F, et al
    Real world efficacy and safety of cabozantinib and vandetanib in advanced medullary thyroid cancer.
    Thyroid. 2020 Aug 11. doi: 10.1089/thy.2020.0206.
    PubMed     Abstract available


  284. HEGEDUS L, Miyauchi A, Tuttle RM
    Non-surgical thermal ablation of thyroid nodules. Not if, but why, when, and how?
    Thyroid. 2020 Aug 10. doi: 10.1089/thy.2020.0659.
    PubMed     Abstract available


  285. ALLOCCA C, Cirafici AM, Laukkanen MO, Castellone MD, et al
    Serine 897 phosphorylation of EPHA2 is involved in signaling of oncogenic ERK1/2 drivers in thyroid cancer cells.
    Thyroid. 2020 Aug 6. doi: 10.1089/thy.2019.0728.
    PubMed     Abstract available


    July 2020
  286. AGATE L, Puleo L, Giani C, Valerio L, et al
    Symptomatic and asymptomatic biliary disorders during lenvatinib treatment for advanced thyroid cancer is an underestimated problem.
    Thyroid. 2020 Jul 29. doi: 10.1089/thy.2020.0245.
    PubMed     Abstract available


  287. MAINO F, Bufano A, Dalmazio G, Campanile M, et al
    VALIDATION OF AMERICAN THYROID ASSOCIATION ULTRASOUND RISK-ADAPTED APPROACH FOR REPEATING CYTOLOGY IN BENIGN THYROID NODULES.
    Thyroid. 2020 Jul 27. doi: 10.1089/thy.2020.0351.
    PubMed     Abstract available


  288. HERNANDEZ-PRERA J, Valderrabano P, Creed J, de la Iglesia JV, et al
    MOLECULAR DETERMINANTS OF THYROID NODULES WITH INDETERMINATE CYTOLOGY AND RAS MUTATIONS.
    Thyroid. 2020 Jul 21. doi: 10.1089/thy.2019.0650.
    PubMed     Abstract available


  289. SASAKI T, Miyauchi A, Ito Y, Kudo T, et al
    Marked decrease over time in conversion surgery after active surveillance of low-risk papillary thyroid microcarcinoma.
    Thyroid. 2020 Jul 14. doi: 10.1089/thy.2020.0319.
    PubMed     Abstract available


  290. BRUCE JY, Bible KC, Chintakuntlawar A
    Emergence of resistant clones in medullary thyroid cancer may not be rescued by subsequent salvage highly selective RET-inhibitor therapy.
    Thyroid. 2020 Jul 14. doi: 10.1089/thy.2020.0449.
    PubMed     Abstract available


  291. YOON JH, Hong AR, Kim HK, Kang HC, et al
    Anaplastic Thyroid Cancer Arising from Dyshormonogenetic Goiter: c.3070T>C and Novel c.7070T>C Mutation in the Thyroglobulin Gene.
    Thyroid. 2020 Jul 6. doi: 10.1089/thy.2020.0248.
    PubMed     Abstract available


  292. AHN J, Jin M, Song E, Ryu YM, et al
    Immune profiling of advanced thyroid cancers using fluorescent multiplex immunohistochemistry.
    Thyroid. 2020 Jul 1. doi: 10.1089/thy.2020.0312.
    PubMed     Abstract available


    June 2020
  293. BERNARDI S, Giudici F, Cesareo R, Antonelli G, et al
    Five-year results of radiofrequency and laser ablation of benign thyroid nodules: a multicenter study from the Italian minimally-invasive treatments of the thyroid group.
    Thyroid. 2020 Jun 24. doi: 10.1089/thy.2020.0202.
    PubMed     Abstract available


  294. CHUNG R, Guan H, Ponchiardi C, Cerda SR, et al
    Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features (NIFTP): Epidemiology and Long-Term Outcomes in a Strictly-Defined Cohort.
    Thyroid. 2020 Jun 16. doi: 10.1089/thy.2019.0616.
    PubMed     Abstract available


  295. BIBLE KC, Menefee ME, Lin CC, Millward M, et al
    An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer.
    Thyroid. 2020 Jun 14. doi: 10.1089/thy.2019.0269.
    PubMed     Abstract available


  296. PARK JH, Choi M, Kim JH, Kim J, et al
    Metabolic syndrome and the risk of thyroid cancer: A nationwide population-based cohort study.
    Thyroid. 2020 Jun 11. doi: 10.1089/thy.2019.0699.
    PubMed     Abstract available


  297. CERIANI L, Milan L, Virili C, Cascione L, et al
    Radiomics analysis of [18F] fluorodeoxyglucose-avid thyroid incidentalomas improves risk stratification and selection for clinical assessment.
    Thyroid. 2020 Jun 10. doi: 10.1089/thy.2020.0224.
    PubMed     Abstract available


  298. CHESOVER AD, Vali R, Hemmati SH, Wasserman JD, et al
    Lung metastasis in children with differentiated thyroid cancer: factors associated with diagnosis and outcomes of therapy.
    Thyroid. 2020 Jun 10. doi: 10.1089/thy.2020.0002.
    PubMed     Abstract available


  299. ZHU CY, Sha SW, Tseng CH, Yang SE, et al
    Trends in the surgical management of known or suspected differentiated thyroid cancer at a single institution, 2010 - 2018.
    Thyroid. 2020 Jun 9. doi: 10.1089/thy.2019.0783.
    PubMed     Abstract available


  300. GUGNONI M, Manicardi V, Torricelli F, Sauta E, et al
    Linc00941 is a novel TGFbeta target that primes papillary thyroid cancer metastatic behavior by regulating the expression of Cadherin 6.
    Thyroid. 2020 Jun 4. doi: 10.1089/thy.2020.0001.
    PubMed     Abstract available


    May 2020
  301. LEE M, Powers AE, Morris LGT, Marti JL, et al
    Reversal in thyroid cancer incidence trends in the United States, 2000-2017.
    Thyroid. 2020 May 27. doi: 10.1089/thy.2020.0321.
    PubMed     Abstract available


  302. TENG D, Li W, Du J, Wang H, et al
    Effects of MWA on Papillary Thyroid Microcarcinoma: A 5-Year Follow-up Report.
    Thyroid. 2020 May 27. doi: 10.1089/thy.2020.0049.
    PubMed     Abstract available


  303. JEON M, You MH, Han JM, Sim SY, et al
    High phosphoglycerate dehydrogenase expression induces stemness and aggressiveness in thyroid cancer.
    Thyroid. 2020 May 22. doi: 10.1089/thy.2020.0105.
    PubMed     Abstract available


  304. HUGHES E, Rhoads A, Thomas A, Aloi J, et al
    Incidence and Survival in Reproductive-Aged Women with Differentiated Thyroid Cancer: United States SEER18 2000-2016.
    Thyroid. 2020 May 12. doi: 10.1089/thy.2020.0152.
    PubMed     Abstract available


  305. HODAK SP, Duh QY
    The American Association of Endocrine Surgeons (AAES) Guidelines for the Definitive Surgical Management of Thyroid Disease in Adults
    Thyroid. 2020 May 10. doi: 10.1089/thy.2020.0209.
    PubMed     Abstract available


  306. CHO SJ, Baek SM, Lim HK, Lee KD, et al
    Long-term Follow-up Results of Ultrasound-guided Radiofrequency Ablation for Low-risk Papillary Thyroid Microcarcinoma: More than 5 year follow-up for 84 tumors.
    Thyroid. 2020 May 7. doi: 10.1089/thy.2020.0106.
    PubMed     Abstract available


  307. HORVATH E, Skoknic Binder V, Majlis Drinberg S, Tala Jury H, et al
    Radioiodine-induced salivary gland damage detected by ultrasonography in patients treated for papillary thyroid cancer: RAI activity and risk.
    Thyroid. 2020 May 6. doi: 10.1089/thy.2019.0563.
    PubMed     Abstract available


  308. AROSEMENA M, Thekkumkattil A, Linares Valderrama MI, Kuker RA, et al
    American Thyroid Association Sonographic Risk and Afirma Gene Expression Classifier Alone and in Combination for the Diagnosis of Thyroid Nodules with Bethesda Category III Cytology.
    Thyroid. 2020 May 2. doi: 10.1089/thy.2019.0673.
    PubMed     Abstract available


    April 2020
  309. FAZELI SR, Zehr B, Amraei R, Toraldo G, et al
    ThyroSeq v2 Testing: Impact on Cytologic Diagnosis, Management, and Cost of Care in Patients with Thyroid Nodule.
    Thyroid. 2020 Apr 29. doi: 10.1089/thy.2019.0191.
    PubMed     Abstract available


  310. CHEN D, Haymart MR
    Disparities research in thyroid cancer: challenges and strategies for improvement.
    Thyroid. 2020 Apr 28. doi: 10.1089/thy.2020.0166.
    PubMed     Abstract available


  311. LEE ZJO, Eslick GD, Edirimanne S
    Investigating anti-thyroglobulin antibody as a prognostic marker for differentiated thyroid cancer: A Meta-Analysis and Systematic Review.
    Thyroid. 2020 Apr 28. doi: 10.1089/thy.2019.0368.
    PubMed     Abstract available


  312. JUNG CK, Jung SH, Jeon S, Jeong YM, et al
    Risk stratification using a novel genetic classifier including <i>PLEKHS1</i> promoter mutations for differentiated thyroid cancer with distant metastasis.
    Thyroid. 2020 Apr 23. doi: 10.1089/thy.2019.0459.
    PubMed     Abstract available


  313. KOTWAL A, Gustafson M, Bornschlegl S, Kottschade L, et al
    Immune checkpoint inhibitor-induced thyroiditis is associated with increased intrathyroidal T lymphocyte subpopulations.
    Thyroid. 2020 Apr 23. doi: 10.1089/thy.2020.0075.
    PubMed     Abstract available


  314. ROTH EM, Lubitz CC, Swan JS, James BC, et al
    Patient-reported quality of life outcome measures in the thyroid cancer population.
    Thyroid. 2020 Apr 15. doi: 10.1089/thy.2020.0038.
    PubMed     Abstract available


  315. STEPHENSON A, Eszlinger M, Stewardson P, McIntyre JB, et al
    Sensitive sequencing analysis suggests TSHR and GNAS as sole driver mutations in hot thyroid nodules.
    Thyroid. 2020 Apr 13. doi: 10.1089/thy.2019.0648.
    PubMed     Abstract available


  316. MUIR C, Menzies AM, J Clifton-Bligh R, Tsang VHM, et al
    Thyroid toxicity following immune checkpoint inhibitor treatment in advanced cancer.
    Thyroid. 2020 Apr 7. doi: 10.1089/thy.2020.0032.
    PubMed     Abstract available


  317. CHEN T, Gilfix B, Rivera JA, Sadeghi N, et al
    The Role of the ThyroSeq v3 Molecular Test in the Surgical Management of Thyroid Nodules in the Canadian Public Healthcare Setting.
    Thyroid. 2020 Apr 3. doi: 10.1089/thy.2019.0539.
    PubMed     Abstract available


  318. POZDEYEV N, Erickson T, Zhang L, Ellison K, et al
    Comprehensive Immune Profiling of Medullary Thyroid Cancer.
    Thyroid. 2020 Apr 3. doi: 10.1089/thy.2019.0604.
    PubMed     Abstract available


    March 2020
  319. FAUSTINO LC, Li CW, Stefan M, Kim K, et al
    A novel mouse model of autoimmune thyroiditis induced by immunization with adenovirus containing full-length thyroglobulin cDNA: Implications to genetic studies of thyroid autoimmunity.
    Thyroid. 2020 Mar 31. doi: 10.1089/thy.2019.0711.
    PubMed     Abstract available


  320. HONG MJ, Na DG, Lee H
    Diagnostic efficacy and safety of core needle biopsy as a first-line diagnostic method for thyroid nodules: a prospective cohort study.
    Thyroid. 2020 Mar 31. doi: 10.1089/thy.2019.0444.
    PubMed     Abstract available


  321. ENDO M, Nabhan F, Angell TE, Harrell M, et al
    Use of Molecular Diagnostic Tests in Thyroid Nodules with Hurthle Cell-Dominant Cytology.
    Thyroid. 2020 Mar 31. doi: 10.1089/thy.2020.0021.
    PubMed     Abstract available


  322. MCKELVEY BA, Gilpatrick T, Wang Y, Timp W, et al
    Characterization of Allele-Specific Regulation of Telomerase Reverse Transcriptase in Promoter Mutant Thyroid Cancer Cell Lines.
    Thyroid. 2020 Mar 31. doi: 10.1089/thy.2020.0055.
    PubMed     Abstract available


  323. RAHMAN S, Pandeya N, Neale RE, McLeod DSA, et al
    Obesity is associated with BRAF V600E-mutated thyroid cancer.
    Thyroid. 2020 Mar 31. doi: 10.1089/thy.2019.0654.
    PubMed     Abstract available


  324. YIN N, Sherman SI, Pak Y, Litofsky D, et al
    The De novo Detection of Anti-thyroglobulin Antibodies and Differentiated Thyroid Cancer Recurrence.
    Thyroid. 2020 Mar 31. doi: 10.1089/thy.2019.0791.
    PubMed     Abstract available


  325. CABANILLAS M, Dadu R, Iyer PC, Wanland KB, et al
    Acquired secondary RAS mutation in BRAFV600E mutated thyroid cancer patients treated with BRAF inhibitors.
    Thyroid. 2020 Mar 26. doi: 10.1089/thy.2019.0514.
    PubMed     Abstract available


  326. SUKPANICH R, Sanglestsawai S, Seib CD, Gosnell JE, et al
    The influence of cosmetic concerns on patient preferences for approaches to thyroid lobectomy: A discrete choice experiment.
    Thyroid. 2020 Mar 24. doi: 10.1089/thy.2019.0821.
    PubMed     Abstract available


  327. PEPLAU E, De Rose F, Reder S, Mittelhaeuser M, et al
    Development of a chimeric Fab directed against human galectin-3 and validation as an immune-PET tracer for the sensitive in vivo imaging of thyroid cancer.
    Thyroid. 2020 Mar 21. doi: 10.1089/thy.2019.0670.
    PubMed     Abstract available


  328. PAPALEONTIOU M, Evron J, Esfandiari N, Reyes-Gastelum D, et al
    Patient Report of Recurrent and Persistent Thyroid Cancer.
    Thyroid. 2020 Mar 18. doi: 10.1089/thy.2019.0652.
    PubMed     Abstract available


  329. PAPALEONTIOU M, Haymart MR
    Too much of a good thing? A cautionary tale of thyroid cancer overdiagnosis and overtreatment.
    Thyroid. 2020 Mar 11. doi: 10.1089/thy.2020.0185.
    PubMed     Abstract available


  330. LI H, Wang Z, Liu JS, Zou BS, et al
    Association between breast and thyroid lesions: a cross-sectional study based on ultrasonography screening in China.
    Thyroid. 2020 Mar 8. doi: 10.1089/thy.2019.0184.
    PubMed     Abstract available


  331. AHMADI S, Gonzalez Sepulveda JM, Talbott M, Reed S, et al
    Patient preferences around extent of surgery in low-risk thyroid cancer: A discrete-choice experiment.
    Thyroid. 2020 Mar 6. doi: 10.1089/thy.2019.0590.
    PubMed     Abstract available


  332. SAWKA AM, Ghai S, Yoannidis T, Rotstein L, et al
    A prospective mixed-methods study of decision-making on surgery or active surveillance for low risk papillary thyroid cancer.
    Thyroid. 2020 Mar 4. doi: 10.1089/thy.2019.0592.
    PubMed     Abstract available


  333. YEH T, Yeung M, Sherman EJ, Tuttle RM MD, et al
    Structural doubling time predicts overall survival in patients with medullary thyroid cancer in patients with rapidly progressive metastatic medullary thyroid cancer treated with molecular targeted therapies.
    Thyroid. 2020 Mar 4. doi: 10.1089/thy.2019.0579.
    PubMed     Abstract available


  334. KIM M, Kim SJ, Xu Z, Ha SY, et al
    <i>BRAF<sup>V600E</i></sup> Transduction of SV40-immortalized Normal Human Thyroid Cell Line Induces Dedifferentiated Thyroid Carcinogenesis in a Mouse Xenograft Model.
    Thyroid. 2020 Mar 2. doi: 10.1089/thy.2019.0301.
    PubMed     Abstract available


    February 2020
  335. YIP L
    Thoughtful Utilization of Molecular Testing in Refining Thyroid Nodule Risk Assessment: Don't Throw Out the Baby.
    Thyroid. 2020 Feb 28. doi: 10.1089/thy.2020.0148.
    PubMed     Abstract available


  336. JHIANG SM, Konda B, Sipos JA, Nabhan F, et al
    Prospects for Re-differentiating Agents in the Use of Radioactive Iodine Therapy for Thyroid Cancer.
    Thyroid. 2020 Feb 27. doi: 10.1089/thy.2020.0143.
    PubMed     Abstract available


  337. PEREIRA MM, Williams VL, Hallanger-Johnson JE, Valderrabano P, et al
    Thyroid Cancer Incidence Trends in the United States: Association with Changes in Professional Guidelines' recommendations.
    Thyroid. 2020 Feb 26. doi: 10.1089/thy.2019.0415.
    PubMed     Abstract available


  338. NIES M, Cantineau AEP, Arts EGJM, van den Berg MH, et al
    Long-Term Effects of Radioiodine Treatment on Female Fertility in Survivors of Childhood Differentiated Thyroid Carcinoma.
    Thyroid. 2020 Feb 20. doi: 10.1089/thy.2019.0560.
    PubMed     Abstract available


  339. CHEN JY, Ji QH, Bai C, Zheng X, et al
    Surufatinib in Chinese patients with locally advanced or metastatic differentiated thyroid cancer and medullary thyroid cancer: A multicenter, open-label, Phase II trial.
    Thyroid. 2020 Feb 19. doi: 10.1089/thy.2019.0453.
    PubMed     Abstract available


  340. NIEDERLE MB, Scheuba C, Riss P, Selberherr A, et al
    Early diagnosis of medullary thyroid cancer: Are calcitonin stimulation tests still indicated in the era of highly sensitive calcitonin immunoassays?
    Thyroid. 2020 Feb 14. doi: 10.1089/thy.2019.0785.
    PubMed     Abstract available


  341. CESAREO R, Pacella CM, Pasqualini V, Campagna G, et al
    Laser Ablation versus Radiofrequency Ablation for benign non-functioning thyroid nodules: Six-month results of a randomised, parallel, open-label, trial (LARA trial).
    Thyroid. 2020 Feb 14. doi: 10.1089/thy.2019.0660.
    PubMed     Abstract available


  342. ZHAO Y, Yu T, Chen L, Xie D, et al
    A Germline <i>CHEK2</i> Mutation in a Family with Papillary Thyroid Cancer.
    Thyroid. 2020 Feb 11. doi: 10.1089/thy.2019.0774.
    PubMed     Abstract available


  343. PEREZ-SOTO RH, Velazquez-Fernandez D, Arellano-Gutierrez G, Chapa Ibarguengoitia M, et al
    Preoperative and postoperative risk stratification of thyroid papillary microcarcinoma. A comparative study between Kuma criteria and 2015 ATA guidelines risk stratification.
    Thyroid. 2020 Feb 7. doi: 10.1089/thy.2019.0698.
    PubMed     Abstract available


  344. REN Y, Kyriazidis N, Faquin WC, Soylu S, et al
    The presence of Hurthle cells does not increase the risk of malignancy in most Bethesda categories in thyroid fine-needle aspirates.
    Thyroid. 2020 Feb 4. doi: 10.1089/thy.2019.0190.
    PubMed     Abstract available


  345. THOMAS J, Haertling T
    AIBx, artificial intelligence model to risk stratify thyroid nodules.
    Thyroid. 2020 Feb 4. doi: 10.1089/thy.2019.0752.
    PubMed     Abstract available


    January 2020
  346. GUAN H, Toraldo G, Cerda SR, Godley FA, et al
    Utilities of RAS mutations in pre-operative fine needle biopsies for decision-making for thyroid nodule management: results from a single-center prospective cohort.
    Thyroid. 2020 Jan 29. doi: 10.1089/thy.2019.0116.
    PubMed     Abstract available


  347. SARACYN M, Lubas A, Bober B, Kowalski L, et al
    <b>Recombinant human thyrotropin worsens renal cortical perfusion and renal function in patients after total thyroidectomy due to differentiated thyroid cancer</b>.
    Thyroid. 2020 Jan 22. doi: 10.1089/thy.2019.0372.
    PubMed     Abstract available


  348. LI M, Brito JP, Vaccarella S
    Long term declines of thyroid cancer mortality: an international age-period-cohort analysis.
    Thyroid. 2020 Jan 22. doi: 10.1089/thy.2019.0684.
    PubMed     Abstract available


  349. LIU L, Zhang X, Tian T, Huang R, et al
    Prognostic value of pre-ablation stimulated thyroglobulin in children and adolescents with differentiated thyroid cancer.
    Thyroid. 2020 Jan 22. doi: 10.1089/thy.2019.0585.
    PubMed     Abstract available


  350. GONZALEZ-VELAZQUEZ CD, O'Malley QF, Yue LE, Urken ML, et al
    Letter to the editor: Treatment decisions in thyroid microcarcinomas: Identifying gaps in knowledge to empower our patients.
    Thyroid. 2020 Jan 22. doi: 10.1089/thy.2019.0451.
    PubMed     Abstract available


  351. PERSICHETTI A, Di Stasio E, Coccaro C, Graziano FM, et al
    Inter- and Intra-Observer Agreement in the Assessment of Thyroid Nodule Ultrasound Features and Classification systems: A Blinded Multicenter Study.
    Thyroid. 2020 Jan 17. doi: 10.1089/thy.2019.0360.
    PubMed     Abstract available


  352. LEE YK, Hwangbo Y, Lee S, Lee DE, et al
    Aspirin use is not associated with lower thyroid cancer risk: A nationwide nested case-control study.
    Thyroid. 2020 Jan 17. doi: 10.1089/thy.2019.0641.
    PubMed     Abstract available


  353. SANABRIA A
    Experience with active surveillance of thyroid microcarcinomalow-risk carcinoma in a developing country.
    Thyroid. 2020 Jan 17. doi: 10.1089/thy.2019.0522.
    PubMed     Abstract available


  354. JACK GA, Sternberg SB, Aronson MD, Mukamal KJ, et al
    <b>Non-Diagnostic Fine-Needle Aspiration Biopsy of Thyroid Nodules: Outcomes and Determinants</b>.
    Thyroid. 2020 Jan 17. doi: 10.1089/thy.2019.0140.
    PubMed     Abstract available


  355. PAPARODIS R, Karvounis E, Bantouna D, Chourpiliadis C, et al
    Incidentally discovered papillary thyroid microcarcinomas are more frequently found in patients with chronic lymphocytic thyroiditis than with multinodular goiter or Graves disease.
    Thyroid. 2020 Jan 17. doi: 10.1089/thy.2019.0347.
    PubMed     Abstract available


  356. MORENO I, Hirsch D, Duskin-Bitan H, Diker-Cohen T, et al
    Response to Therapy Assessment in Intermediate-Risk Thyroid Cancer Patients- Is rhTSH Stimulation Required?
    Thyroid. 2020 Jan 13. doi: 10.1089/thy.2019.0431.
    PubMed     Abstract available


  357. HE H, Li W, Comiskey DF Jr, Liyanarachchi S, et al
    A truncating germline mutation of TINF2 in individuals with thyroid cancer or melanoma results in longer telomeres.
    Thyroid. 2020 Jan 13. doi: 10.1089/thy.2019.0156.
    PubMed     Abstract available


  358. VAN VELSEN EFS, Visser WE, van den Berg S, Kam BLR, et al
    Longitudinal Analysis of the Effect of Radioiodine Therapy on Ovarian Reserve in Females with Differentiated Thyroid Cancer.
    Thyroid. 2020 Jan 13. doi: 10.1089/thy.2019.0504.
    PubMed     Abstract available


  359. OH JM, Baek SH, Gangadaran P, Hong CM, et al
    A novel tyrosine kinase inhibitor can augment radioactive iodine uptake through endogenous sodium/iodide symporter (NIS) expression in anaplastic thyroid cancer.
    Thyroid. 2020 Jan 13. doi: 10.1089/thy.2018.0626.
    PubMed     Abstract available


  360. ZAFEREO M, McIver B, Vargas S, Dominguez Ruiz-Tagle JM, et al
    A THYROID GENETIC CLASSIFIER CORRECTLY PREDICTS BENIGN NODULES WITH INDETERMINATE CYTOLOGY: TWO-INDEPENDENT MULTICENTER, PROSPECTIVE VALIDATION TRIALS.
    Thyroid. 2020 Jan 7. doi: 10.1089/thy.2019.0490.
    PubMed     Abstract available


  361. ZHANG M, Tufano RP, Russell J, Zhang Y, et al
    Ultrasound-guided radiofrequency ablation versus surgery for low risk papillary thyroid micro-carcinoma: results of over 5 years follow-up.
    Thyroid. 2020 Jan 7. doi: 10.1089/thy.2019.0147.
    PubMed     Abstract available


  362. SUGINO K, Nagahama M, Kitagawa W, Ohkuwa K, et al
    Risk stratification of pediatric patients with differentiated thyroid cancer: Is total thyroidectomy necessary for patients at any risk? .
    Thyroid. 2020 Jan 7. doi: 10.1089/thy.2019.0231.
    PubMed     Abstract available


  363. JASIM S, Baranski T, Teefey S, Middleton WD, et al
    Investigating the effect of thyroid nodule location on the risk of thyroid cancer.
    Thyroid. 2020 Jan 7. doi: 10.1089/thy.2019.0478.
    PubMed     Abstract available


  364. YOSHIDA Y, Horiuchi K, Okamoto T
    Patients' view on the management of papillary thyroid microcarcinoma: active surveillance or surgery.
    Thyroid. 2020 Jan 7. doi: 10.1089/thy.2019.0420.
    PubMed     Abstract available


  365. JENSEN CB, Saucke MC, Francis DO, Voils CI, et al
    From Overdiagnosis to Overtreatment of Low-risk Thyroid Cancer: A Thematic Analysis of Attitudes and Beliefs of Endocrinologists, Surgeons, and Patients.
    Thyroid. 2020 Jan 7. doi: 10.1089/thy.2019.0587.
    PubMed     Abstract available


    December 2019
  366. YUAN Q, Wu G, Hou J, Liao X, et al
    Correlation between electrophysiological changes and outcomes of vocal cord function in 1764 recurrent laryngeal nerves with visual integrity during thyroidectomy.
    Thyroid. 2019 Dec 27. doi: 10.1089/thy.2019.0361.
    PubMed     Abstract available


  367. PARIHAR AS, Mittal BR, Kumar R, Shukla J, et al
    68Ga-DOTA-RGD2 PET/CT in radioiodine (131I) refractory thyroid cancer - Prospective comparison of diagnostic accuracy with 18F-FDG PET/CT and evaluation towards potential theranostics.
    Thyroid. 2019 Dec 23. doi: 10.1089/thy.2019.0450.
    PubMed     Abstract available


  368. JUN JK, Hwang SY, Hong S, Suh M, et al
    Association of screening by thyroid ultrasonography with mortality in thyroid cancer: a case-control study using data from two national surveys.
    Thyroid. 2019 Dec 23. doi: 10.1089/thy.2019.0460.
    PubMed     Abstract available


  369. MASAKI C, Sugino K, Saito N, Akaishi J, et al
    Efficacy and limitations of lenvatinib therapy for radioiodine-refractory differentiated thyroid cancer: real-world experiences.
    Thyroid. 2019 Dec 19. doi: 10.1089/thy.2019.0221.
    PubMed     Abstract available


  370. NERVO A, Ragni A, Gallo M, Ferraris A, et al
    SYMPTOMATIC BILIARY DISORDERS DURING LENVATINIB TREATMENT FOR THYROID CANCER: AN UNDERESTIMATED PROBLEM?
    Thyroid. 2019 Dec 19. doi: 10.1089/thy.2019.0355.
    PubMed     Abstract available


  371. CRAIG SJ, Bysice A, Nakoneshny SC, Pasieka JL, et al
    THE IDENTIFICATION OF INTRA-OPERATIVE RISK FACTORS CAN REDUCE, BUT NOT EXCLUDE, THE NEED FOR COMPLETION THYROIDECTOMY IN LOW-RISK PAPILLARY THYROID CANCER PATIENTS.
    Thyroid. 2019 Dec 6. doi: 10.1089/thy.2019.0274.
    PubMed     Abstract available


  372. CHOI Y, Jung SL
    Efficacy and safety of thermal ablation techniques for the treatment of primary papillary thyroid microcarcinoma: a systematic review and meta-analysis.
    Thyroid. 2019 Dec 4. doi: 10.1089/thy.2019.0707.
    PubMed     Abstract available


  373. PARK JL, Jeon S, Seo E, Bae DH, et al
    Comprehensive DNA methylation profiling identifies novel diagnostic biomarkers for thyroid cancer.
    Thyroid. 2019 Dec 4. doi: 10.1089/thy.2019.0011.
    PubMed     Abstract available


  374. VYDRO L, Kitahara CM, Lubin JH, Schneider AB, et al
    Among Individuals Irradiated for Benign Conditions in Childhood, Developing Thyroid Cancer Does Not Affect All-cause Survival.
    Thyroid. 2019 Dec 4. doi: 10.1089/thy.2019.0439.
    PubMed     Abstract available


    October 2019
  375. MASOODI T, Siraj AK, Siraj S, Azam S, et al
    Whole Exome Sequencing of Matched Primary and Metastatic Papillary Thyroid Cancer.
    Thyroid. 2019 Oct 31. doi: 10.1089/thy.2019.0052.
    PubMed     Abstract available


  376. FUZIWARA CS, Saito KC, Kimura ET
    Thyroid follicular cell loss of differentiation induced by miRNA miR-17-92 cluster is attenuated by CRISPR/Cas9n gene silencing in anaplastic thyroid cancer.
    Thyroid. 2019 Oct 3. doi: 10.1089/thy.2018.0601.
    PubMed     Abstract available


  377. JAIN NK, Mostoufi-Moab S, Hawkes CP, Nelson ND, et al
    Extrathyroidal Extension is an Important Predictor of Regional Lymph Node Metastasis in Pediatric Differentiated Thyroid Cancer.
    Thyroid. 2019 Oct 1. doi: 10.1089/thy.2019.0229.
    PubMed     Abstract available


    September 2019
  378. IANNI F, Pascucci D, Paragliola RM, Rota CA, et al
    Follow-up or surgery for indeterminate thyroid nodules: could the CUT score application be a support for decision making in the preoperative assessment?
    Thyroid. 2019 Sep 25. doi: 10.1089/thy.2018.0649.
    PubMed     Abstract available


  379. ZAHEDI A, Bondaz L, Rajaraman M, Leslie WD, et al
    Risk for Thyroid Cancer Recurrence Is Higher In Men Than In Women Independent of Disease Stage At Presentation.
    Thyroid. 2019 Sep 16. doi: 10.1089/thy.2018.0775.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Head and Neck Cancer is free of charge.